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PULMONARY FUNCTION TESTS IN TYPE 2 DIABETIC PATIENTS 
UNDERGOING MAJOR ABDOMINAL SURGERIES UNDER 
GENERAL ANESTHESIA 
ABSTRACT 
Background: Diabetes mellitus is a systemic disease. Among the various 
organs affected by diabetes, lung is also included. Pulmonary function tests can 
be assessed by spirometry preoperatively which helps in better outcome of the 
diabetic patients postoperatively. 
Aims and objectives: The aim of the study is to evaluate the pulmonary 
function tests in type 2 diabetic patients undergoing elective major abdominal 
surgeries under general anesthesia. 
Materials and methods: Fifty type 2 diabetic patients and fifty non-diabetic 
patients in the age group of 40-60 yrs undergoing elective major abdominal 
surgeries under general anesthesia were selected for the study. General 
anesthesia was standardised for both the groups. Pulmonary function tests were 
performed 60 minutes before and 60 minutes after the end of surgery. In the 
diabetic group, patients with duration of diabetes of 5-15 yrs were selected for 
the study. The pulmonary function tests recorded were FEV1, FVC, 
FEV1/FVC, FEF 25%, Peak expiratory flow rate(PEFR). 
Results: The pulmonary function tests were significantly reduced in diabetic 
patients both preoperatively and postoperatively when compared to non-diabetic 
patients. 
Conclusion: Diabetes mellitus being a systemic disease,affects lungs causing 
ventilatory abnormalities probably because of glycosylation of connective 
tissues, reduced pulmonary elastic recoil and inflammatory changes in the 
lungs. 
KEY WORDS: Diabetes mellitus, Pulmonary function tests, General 
anesthesia.  
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INTRODUCTION 
Diabetes mellitus is a systemic disease. It affects many  organ systems in 
the human body. Among the various systems affected, respiratory system is also 
included.  It is both a microvascular and also a macrovascular disease.  In 
diabetes, the alveolar capillary network in the lung may be affected by 
microangiopathic changes. As this network has a large reserve , these 
microangiopthic changes may go unrecognised clinically. Symptoms such as 
dyspnoea develops only in the late stages of the disease.  
                  Pulmonary functions can be assessed by spirometry. The pulmonary 
function tests includes both static and dynamic tests. The pulmonary function 
tests can be used for diabetic patients undergoing major surgeries such as 
cardiothoracic  and abdominal surgeries. The status of the respiratory system 
can be assessed preoperatively by doing this test. It helps to optimise the 
patients preoperatively. The preoperative optimisation includes regular 
breathing  exercises and control of blood glucose level. This results in better 
postoperative outcome of the diabetic patients .  In this study , we evaluate the 
pulmonary function tests both preoperatively and postoperatively in type 2 
diabetic patients  undergoing elective major abdominal surgeries under general 
anesthesia  and compare them with the non diabetic patients undergoing elective 
major abdominal surgeries under general anesthesia.     
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AIM OF THE STUDY 
 
             The aim of the study is to evaluate the pulmonary function tests in type 
2 diabetic patients undergoing elective major abdominal surgeries under general 
anesthesia.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
ANATOMY OF RESPIRATORY SYSTEM 
 
The respiratory tract is divided into upper and lower respiratory tract. 
UPPER RESPIRATORY TRACT: 
            This consists of following components. 
1. Nasal Passages. 
2. Sinuses. 
3. Pharynx. 
4. Epiglottis. 
5. Larynx. 
The important functions of the upper airway are: 
• Conducting the air to the lower airway. 
• Protecting the lower airway from the foreign materials such as food or 
liquids soiling it. 
• Warming, filtering and humidifying the inspired air for efficient gaseous 
exchange. 
NASAL PASSAGES: 
         The two nasal cavities start in front from the external nares and end 
posteriorly in the nasopharynx. The structure of the nose with its two nasal 
cavities, turbinates and rich blood supply provide maximum contact between 
the inspired air nasal mucosa for the humidification of air. In the anterior part of 
the nasal fossa with its stiff hairs and spongy mucous membrane and the ciliated 
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epithelium provides a powerful defence against the invasion of any organism. 
The most important factor in the prevention of accumulation of secretions 
throughout the respiratory tract is the continuous activity of cilia. The absence 
of moisture even for a few minutes leads to ciliary activity cessation. 
SINUSES: 
              The sinuses and paranasal sinuse play  an important role in modifying 
the quality of the air which is breathed during normal respiration. Sinuses  
decreases the weight of the skull, providing mucous for the nasal cavity and also 
act as resonant chambers of voice. The paranasal sinuses are lined with ciliated 
mucous producing cells and have small pathways known as meatus which 
communicates with the nasal cavity. 
PHARYNX: 
             The pharynx is a common passage for food and air to pass through to 
take part their respective route. When a patient becomes unconscious, the area 
which gets obstructed is the pharynx. There are three divisions in the pharynx 
namely nasopharynx, oropharynx and hypopharynx. The main difficulty in 
maintaining a perfect airway in an unconscious patient is the tendency of the 
tongue to fall backwards obstructing the laryngeal opening.  
For obtaining a clear airway two separate maneuvers are needed to 
provide perfect airway in the unconscious patient. First one is, the lower jaw 
must be carried forwards and upwards so that the lower incisor lie in front of the 
upper incisor. This is known as Prognathic attitude. The second one is, the head 
5 
 
is hyperextended so that the tongue is carried farther upward and forward which 
is away from the posterior pharyngeal wall. 
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This Diagram shows various structures of the upper respiratory tract 
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LARYNX: 
               Larynx is the organ of phonation. The larynx lies at the level of 3rd to 
6th cervical vertebra and consists of a number of articulated cartilages 
surrounding the upper end of trachea. The vocal cords in the larynx provides 
phonation. The larynx also provides sphincter function which prevents 
aspiration. The cartilages of larynx are thyroid, arytenoids and cricoid. The 
thyroid cartilage is the largest and protects the important structures of the larynx 
from any damage. The cricothyroid membrane is incised to perform 
Cricothyroidotomy which is an emergency procedure done for the obstruction 
of upper airway. The arytenoids cartilage provides attachment for vocal cord 
ligaments. The glottis is the space between the two vocal cords. The epiglottis is 
a leaf like cartilaginous structure which extends from the base of the tongue to 
the thyroid cartilage by ligaments. The epiglottis flaps down during swallowing 
to direct the swallowed material into the esophagus thus guarding the opening 
of the larynx. 
LOWER RESPIRATORY TRACT: 
                   The lower respiratory tract consists of the trachea which is 
considered as the downward continuation of the larynx. The trachea divides into 
right and left main bronchus which leads on to the right and left lungs. The main 
bronchus gives branches for the individual lobes of the lungs. The lobar bronchi 
branches into lobular bronchi which finally divides into smaller tube like 
structures resembling the branches of a tree becoming smaller and shorter. The 
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functions of the lower respiratory tract are to conduct air down to the alveoli  to  
provide mucociliary defence. 
TRACHEA: 
                The trachea is a tube made up of rings of cartilages which are 
incomplete posteriorly. The posterior part of the trachea is made up of smooth 
muscle and lies just adjacent to the esophagus. Any excessive pressure on this 
smooth muscle , for example, cuff of an endotracheal tube or tracheostomy tube 
leads to erosion causing trachea-esophageal fistula. The trachea is about 10-11 
cm long extending from the lower part of the larynx opposite to the level of the 
6th cervical vertebra to the point where it bifurcates into right and left main 
bronchus at the carina at the level of upper border  of 5th thoracic vertebra. In 
children the carina is at the level of 3rd costal cartilage. The trachea is lined by 
ciliated columnar epithelium and mucous secreting goblet cells. The upper two 
thirds of the trachea is supplied by inferior thyroid artery and the lower one 
third is supplied by the bronchial arteries. The trachea can move with 
respiration  and changes in position with the movement of the head. 
                 On the basis of their function lower airway is divided into  
1. Conducting airways. 
2. Respiratory zone. 
The conducting airways is the non alveolate  region  and  the respiratory zone is 
the alveolate region. The main bronchus is taken as division 1 and the 
subsequent divisions are numbered as 2,3 and  so on. The divisions are also 
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known as generation. Approximately the first 16 divisions of the 
tracheobronchial tree does not take part in gas exchange and  so they are named 
as the conduction zone. The volume of air in this zone is approximately 150 ml  
and this is known as the anatomical dead space. 
                The right main bronchus starts from the trachea at an angle of 25 
degrees from  the vertical. This enters the right lung opposite to T5.  The right 
upper lobe bronchus starts just 2.5 cm from the carina. This position promotes  
more chances for the aspiration of foreign material into the right lung. In adults, 
the narrowest portion is the glottis and in children the narrowest portion is the 
cricoid ring. After entering the lung the right main bronchus divides into 3 lobar 
bronchi which again divides into upper, middle and lower right lung lobes. The 
right upper lobe consists of three segments- apical, posterior and anterior 
segments. The right middle lobe consists of two segments- lateral and medial 
segments. The right lower lobe consists of five segments- apical, medial  basal,  
anterior basal, lateral basal and posterior basal segments. 
             The left main bronchus is longer and narrower than the right main 
bronchus  and lies more horizontal to the trachea. The length of the left  main 
bronchus before the origin of upper lobe bronchus is 5cm. The left main 
bronchus  leaves  the trachea at an angle of about 45 degrees and enters the lung 
opposite to T6. The left main bronchus divides  into upper and lower lobe 
bronchi. The left upper lobe consists of five segments – apical, posterior, 
anterior, superior and inferior segments. The left lower lobe consists of               
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3 segments- apical, anterior  basal lateral basal and posterior basal segments. 
The lobar bronchi bifurcates into segmental bronchioles or terminal bronchioles  
which leads on to the lung segments. 
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LOWER RESPIRATORY TRACT 
 
 
This Diagram shows various structures of the lower respiratory tract 
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RESPIRATORY ZONE: 
                The respiratory zone starts from the 17th zone of the bronchial tree. It 
consists of  
• Terminal bronchiole. 
• Respiratory bronchiole. 
• Alveolar ducts or passages. 
• Atria. 
• Air sacs. 
• Air cells. 
The alveoli are lined with a single molecular layer of phospholipids 
known as phosphotidyl choline which is the major content of surfactant. 
The surfactant is a substance that reduces the surface tension  of the 
alveoli. 
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PHYSIOLOGY OF RESPIRATORY SYSTEM: 
        Respiration is nothing  but  the gaseous exchange between an organism and 
its environment. Here, oxygen is absorbed and carbon dioxide is removed that 
involves two components. The diffusion of gases at the alveolar capillary 
membrane is known as external respiration and the diffusion of gases across the 
cell membrane is known as internal respiration. The carbon dioxide which is 
removed from the tissues is carried by the blood to the lungs where it is 
eliminated by external respiration. For adequate gaseous exchange to take place 
the lung has to be well perfused with deoxygenated  blood from the pulmonary 
artery.There are three main integral parts of external respiration. They are: 
• Ventilation which means moving of air in and out of lungs. 
• Perfusion which is adequate blood flow to all parts of the lung. 
• Diffusion which is exchange of gases across the alveolar capillary 
membrane. 
The factors modifying the diffusion of gases across the alveolar capillary 
membrane are the surface area of the membrane, the thickness of the membrane, 
the pressure gradient between the two sides of the membrane, the diffusion 
coefficient of the gas. The lung has enormous surface area for gas exchange. At 
rest, for enough gas exchange to take place,5 healthy segments out of 19 
segments is sufficient.  
           Increase in the thickness of the alveolar capillary membrane causes 
difficulty in diffusion. This can occur in chronic fibrotic lung diseases, 
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pulmonary edema, diabetes mellitus etc.  At rest, blood passes through the 
capillaries in approximately 0.5 to 0.75 seconds.  But it is estimated that when 
the blood has travelled only one fourth of the capillary distance, the gas 
exchange is completed. This is the reason which provides reserve time for gas 
exchange in conditions like disease and exercise states. In conditions like 
alveolar congestion, interstitial or alveolar edema, pulmonary fibrosis the 
diffusion distance and time may be increased. 
              The partial pressure of oxygen in the alveolus is 100 mm Hg and the 
partial pressure of oxygen in the pulmonary capillary is 40 mm Hg. Therefore, a 
pressure gradient of 60 mm Hg is present for oxygen to diffuse into the 
pulmonary blood to reach the equilibrium. Similarly, a pressure gradient of 6 
mm Hg causes easy diffusion of carbon dioxide as it is 20 times more diffusible 
than oxygen into the alveoli. 
 
ALVEOLAR PCO2: 
                              The alveolar pco2 is expressed as PACO2. At rest, the normal 
oxygen uptake is 250ml/minute and the normal CO2 production is 
200ml/minute. CO2 diffuses from the pulmonary artery to the alveoli where the 
PACO2 is determined by its rate transfer and its dilution by alveolar ventilation. 
PaCO2 rises at a rate of 3 to 6 mm Hg during apnoea. 
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ALVEOLAR PO2: 
    Alveolar po2 is expressed as PAO2.The main factor which influences 
the alveolar PAO2 is the barometric pressure. The normal barometric pressure is 
760 mm Hg. The normal saturated pressure of water vapour in the alveoli is 47 
mm Hg. As one goes to the high altitude the barometric pressure decreases. At 
63000 feet, the barometric pressure is 47mm Hg so that PIO2 becomes zero and 
therefore blood starts boiling. When the cardiac output decreases, the perfusion 
to the lung decreases which decreases the uptake of oxygen and therefore PAO2 
will tend to increase. 
OXYGEN CARRIAGE IN BLOOD: 
The saturation of oxygen in haemoglobin for different partial pressures of 
oxygen to which the oxygen is exposed is not linear.  The haemoglobin is 97% 
saturated with oxygen at 90 to 100 mm Hg. At partial pressures of 60 mm Hg, 
the saturation is 90%. The partial pressure of oxygen with the percentage 
saturation of haemoglobin can be compared with oxygen dissociation curve. As 
the shape of the curve is S shaped , it is possible for the PO2 to be reduced with 
only minimal effect on the saturation. But when a certain point is reached the 
saturation begins to fall rapidly with only a small reduction in PO2. The shift of 
the curve to the left or right will have a significant effect on the availability of 
oxygen to the tissues. At a lower level of  saturation, haemoglobin readily 
combines with oxygen  to the tissues which is of great advantage for the 
delivery of oxygen to the tissues. P50 is the partial pressure of oxygen required 
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for 50% saturation of haemoglobin. Normally it is 26 mm Hg. Conditions where 
oxygen haemoglobin dissociation curve is shifted to right are acidosis, 
hypercarbia, hyperthermia, anemia, chronic hypoxia, stored blood. The 
conditions which shift the oxygen haemoglobin dissociation curve to the left are 
alkalosis, hypothermia, reduction in 2,3-Diphosphoglycerate levels. When fully 
saturated, 1 gram of haemoglobin carries 1.34 ml of oxygen.  To this 0.3 ml of 
oxygen which is carried in the form of physical solution has to be added. When 
the PO2 decreases below 27 mm Hg in a normal person the consciousness is 
likely to be lost. 
OXYGEN FLUX: 
The rate of oxygen carriage in the arterial blood is known as oxygen flux. 
It is also defined as the amount of oxygen leaving the left ventricle per minute 
in the arterial blood. This can be calculated as                                             
Cardiac output(ml/min)  X  SaO2  X  Hb concentration (gm/ml) X 1.34. 
The normal value of oxygen flux is 1000ml/min. When this value is below 
400ml/min and if it continues for long time it is dangerous. In this 1000 ml, 250 
ml is used up for cellular metabolism and the remaining returns to the lungs in 
the mixed venous blood  and therefore this  blood is about 75% saturated with 
oxygen. 
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CARBON DIOXIDE TRANSPORT: 
            The proteins in the plasma combines with carbon dioxide to form 
carbamino compounds. The remaining carbondioxide is either transported in 
simple solution or as bicarbonate ion. Normally, 10 ml of blood carries 3 ml of 
carbondioxide. Carbondioxide is 20 times more diffusible than oxygen. The 
absolute requirement for the elimination of carbondioxide is the alveolar 
ventilation. Inhalation of 5% carbondioxide for a long time even though it is 
unpleasant, usually will not produce any ill effects but when the concentration is 
raised to 15%, unconsciousness occurs. At this level, muscle rigidity and 
tremors can occur. When the concentration of CO2 raises to 20-30% generalised 
convulsions can be produced. 
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EFFECT OF GENERAL ANESTHESIA ON RESPIRATORY SYSTEM 
 When a patient undergoes surgery under general anesthesia , whether the 
patient is on controlled ventilation or spontaneous ventilation , most of the 
patients suffer some degree of impairment in the arterial oxygenation. This 
impairment becomes more significant in elderly patients, obese patients and in 
smokers. In healthy young and middle aged patients undergoing surgeries under 
general anesthesia, venous admixture or shunt has been found to be only 10% 
and the scatter in ventilation to perfusion ratio (V/Q) has been found to be 
minimal. But in patients who has significant deterioration in the pulmonary 
functions preoperatively,general  anesthesia  causes widening in the VA/Q  
distribution and also the shunt. 
             When the depth of anesthesia is increased in patients on general 
anesthesia  the following changes are noted in respiration. At lighter planes of 
anesthesia, the respiratory patterns may vary from hyperventilation to 
vocalisation to breath holding. As the depth of anesthesia increases and equals 
to that of minimum alveolar concentration, the normal respiration follows but 
with a larger tidal volume.  With further progression in the depth of anesthesia, 
the regular respiration is interrupted but inspiratory pause is partial at end 
expiration- hitch in the inspiration followed by prolonged expiratory phase 
indicated by arrows. With further deepening of anesthesia, the respiration 
becomes faster, more regular but shallow breathing. Later becomes sine wave. 
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Both opioids and benzodiazepines produces respiratory depression but opioids 
depresses the respiratory rate and benzodiazepines decreases the tidal volume. 
                 When halogenated agents are used, the patient is in deep anesthesia 
and the increased depression is manifested by rapid shallow breathing . This is 
known as panting.  As the anesthetic depth deepens , the support provided by 
the intercostal muscles is lost leading to the rocking boat movement. Here, there 
is an out of phase depression of chestwall during inspiration  and there is 
bellowing of the abdomen. If the patient is on spontaneous ventilation, as the 
anesthetic depth deepens with halothane , the increasing concentration of 
halothane displaces the end tidal CO2 concentration.,  PCO2-ventilation 
response curve progresses to the right shifting the apnoeic threshold to a higher 
end tidal CO2 concentration. 
                The pre-existing diseases such as pulmonary infections, lung collapse, 
sepsis, cardiac failure, renal failure and heavy smokers  determines the effect of 
anesthesia on the respiratory functions. Here, the relationship between 
functional residual capacity(FRC) and closing capacity(CC) is important.  In 
healthy patients FRC exceeds that of CC by 1 litre.  But in obese patients , 
elderly and in patients with chest wall deformities , CC is 0.5-0.75 litres less 
than FRC. After induction of anesthesia with a 1 litre decrease in FRC, there 
will be no change in the relationship between FRC and CC  in a healthy patient.  
But in patients with respiratory disturbances, a decrease in FRC will cause the 
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CC to increase more than FRC and causes a low ventilation perfusion ratio or an 
atelectatic FRC-CC relationship. 
            If an anesthetic drug inhibits Hypoxic pulmonary vasoconstriction 
(HPV) , the drug causes increased shunting in patients with pre-existing HPV 
than in patients without pre-existing HPV. Thus the effect of standard anesthetic 
produces varying degrees of respiratory changes in patients who have different 
degrees of pulmonary dysfunction. The position of the patients such as 
lithotomy, jack knife and kidney rest position may decrease the cardiac output  
and causes hypoventilation in spontaneously breathing patients leading on to 
decrease in FRC. FRC refers to the volume of the air remaining in the lungs 
after a normal, passive expiration. The loss of chest wall compliance or lung 
compliance results in reduced FRC. Anesthesia and abdominal surgeries 
produces  a progressive upward displacement of the diaphragm . This upward 
displacement of diaphragm  is due to  loss of respiratory muscle tone  which 
allows  the abdominal content to push the diaphragm upwards. This results in   
reduced FRC and development of intraoperative atelectasis, intrapulmonary 
shunting, and hypoxemia. The head down position of the patient, type of 
surgery  such as abdominal surgery or laparoscopy with insufflation , concurrent 
use of muscle relaxants  can  further cause the diaphragmatic shift upwards.  
The anatomical dead space increases because of the increase in peak airway 
pressure and expansion of the bronchial tree. Anesthesia cause more dangerous   
effects on respiratory function in obese subjects than in normal patients.  For 
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determining the lung volume, oxygenation and respiratory mechanics body 
mass is important. The volume of decrease in FRC with atelectasis has been 
found to be related to age, weight, and size .The airway resistance is 
approximately twice as high in patients with severe obesity compared with 
those with minimal obesity.  Moderate to severe hypoxemia has been found in 
supine obese subjects during spontaneous breathing, anesthesia and when the 
patient is paralysed. .  Ventilation-perfusion mismatch is seen in awake, sitting   
and obese subjects. 
                If FRC reduces below closing capacity, airway closure can occur. In 
this case, the lung bases are well perfused, but the ventilation is poor because of 
airway closure and collapse of the alveoli. This causes increases ventilation-
perfusion mismatch and favours formation of compression and absorption 
atelectasis, leading to hypoxemia.  
                 High inspired oxygen concentrations causes significant atelectasis. 
There is a progressive reduction in lung compliance during anesthesia in 
patients with either spontaneous breathing or mechanically ventilated patients.  
The decrease in lung compliance is accompanied by decreasing alveolar oxygen 
tensions. The atmosphere is composed of 78% nitrogen and 21% oxygen. As 
exchange of oxygen takes place at the alveolar-capillary membrane, nitrogen is 
a major component contributing for the inflation of alveoli.  When nitrogen in 
the lungs is replaced with oxygen in a larger volume, for example, when the   
patient is breathing 100% oxygen, the oxygen may get absorbed into the blood   
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thus decreasing the volume of the alveoli, which results in alveolar collapse. 
This is known as absorption atelectasis. Pulmonary atelectasis develops in the 
most dependent part of the lungs during general anesthesia in 90% of the 
patients with normal lung function, and this is considered as the major cause of 
impairment of gas exchange and reduction of lung compliance.  The 
development of atelectasis during anesthesia is attributed to both absorption 
atelectasis and compression of lung tissue as a result of high inspired oxygen 
concentrations. In the postoperative period also, atelectasis plays an important 
role.   
        Inhalational anesthetics inhibits hypoxic pulmonary vasoconstriction 
(HPV). Hypoxic pulmonary vasoconstriction is a physiological phenomenon in 
which pulmonary arteries constrict in response to hypoxia without hypercapnia 
redirecting the blood flow to the alveoli with aaequate ventilation.  Intravenous 
anesthetic agents does not inhibit hyoxic pulmonary vasoconstriction. The HPV 
response may be masked by concurrent changes in cardiac output, contraction 
of myocardium, vascular tone, blood volume distribution, blood pH and CO2 
tension, and lung mechanics. The inhalational anesthetics isoflurane and 
halothane depress the HPV response by 50% at two times minimum alveolar 
concentration (MAC) without any significant decrease in cardiac output. 
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 PULMONARY FUNCTION TESTS 
HISTORICAL ASPECTS: 
             The concept of spirometry goes back to the period of 129-200 AD, 
when Claudius Galen performed volumetric experiments on human ventilation. 
           Giovanni Alfonso Borelli in the year 1681, measured the volume of 
inspired air in one breath by sucking a liquid in a cylindrical tube. 
In the year 1718, Jurin J.  Blew air into bladder and measured the volume 
of air present in the bladder by the principles of Archimedes. He measured the 
tidal volume of 650 ml and maximum expiration of 3610 ml. 
In the year 1796, Menzies R. determined the tidal volume by using the 
method of body plethysmography. 
In the year 1799, Pepys WHJ.found  that the tidal volume to be 270 ml by 
using two mercury gasometers and one water gasometer. 
          In the early 1800’s Sir Humphrey Davy was the person who measured his 
own vital capacity and tidal volume and found it to be 3110 ml and 210 ml with 
a gasometer. He also measured the residual volume by hydrogen dilution 
method which was found to be 590 ml. 
          In the year 1813, Kentish E. was the person who used a simple 
“pulmometer” to study ventilator volumes in disease. 
          It was in the year 1852, Hutchinson John, who designed the first 
spirometer, a water spirometer which is used till date along with few alterations. 
24 
 
The first measurement of Vital Capacity was made by him. He also showed the 
linear relationship of vital capacity to height. 
Wintrich was the person who developed a modified spirometer, concluding that 
3 parameters determine the vital capacity. These parmeters are height, weight 
and age of the individual. 
             Smith E. in the year 1859 developed a portable spirometer. 
            In the year 1866, Salter added the kymograph to the spirometer to record 
time and volume. 
           Gad J.in 1879 introduced a Pneumatograph which allowed to register the 
volume changes of thorax during inspiration and expiration in addition to the 
known parameters and he named it as Aeroplethysmograph. 
Brodie T.G in 1902, used a dry bellow spirometer. 
Tissot in the year 1904, introduced a close circuit spirometer. 
          In 1929, Knipping introduced a standardised method for spiroergometer. 
Tiffnean in 1948, introduced Forced Expiratory Volume (FEV) as a useful lung 
function test. 
          Wright B.M and McKerrow C.B in 1959, introduced the peak flowmeter. 
          Computerised spirometer was introduced in the year 1990. 
Pulmonary function tests are an important investigation in the management of 
patients with major respiratory diseases which are either suspected or diagnosed 
previously. They help us in the diagnosis, to monitor the response to treatment 
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and to plan for further intervention. For the interpretation of pulmonary function 
test, a thorough knowledge of respiratory physiology is needed. 
INDICATIONS: 
1. It can be done in patients whose symptoms are suggestive of respiratory 
disease. These symptoms include cough, cracles, wheeze, breathlessness, 
abnormal chest x ray. 
2. It can be done in patients to monitor for the progression and response to 
treatment to a particular pulmonary disease. These diseases include 
Interstitial fibrosis, COPD, Asthma, pulmonary vascular diseases. 
3. It can be done in patients having connective tissue disorders, neuromuscular 
disorders who may have some respiratory complications. 
4. It can be done for the preoperative evaluation before Lung resection, 
cardiothoracic and abdominal surgeries. 
5. It can be done to evaluate the patients who are at risk for lung diseases. 
6. It can be done to assess for any infection, obliterative bronchiolitis  and  
acute rejection  in patients who had undergone lung transplantation. 
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CONTRAINDICATIONS FOR PERFORMING PULMONARY FUNCTION 
TESTS: 
1. Pneumothorax. 
2. Recent Myocardial Infarction within last one month. 
3. Unstable Angina. 
4. Recent thoracic surgeries. 
5. Recent eye surgeries. 
6. Aortic or Thoracic aneurysm. 
LIMITATIONS OF PULMONARY FUNCTION TESTS: 
1. As with any other tests, there is some variability in the normal predictive 
value. 
2. Unlike any other tests, the accuracy of the pulmonary function tests 
depends on the well trained technician as well as cooperation of the 
patients.  Patients should use their maximum efforts and at the same time 
the technician should be able to recognize submaximal efforts. 
3. Pulmonary function tests must be interpreted along with proper history, 
clinical examination and other diagnostic tests .When this test is used 
alone they usually cannot distinguish among the potential causes of the 
abnormalities. 
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                                             SPIROMETER 
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REQUIREMENTS FOR GOOD PULMONARY FUNCTION TESTS: 
       The American Thoracic Society (ATS) has published certain guidelines 
for the standardization of spirometry apparatus and performance that should 
include acceptability and reproducibility criteria. As spirometry is an effort 
dependent test, each and every spirogram should be examined by using the 
performance criteria published by the ATS. 
1. There should be lack of artefact caused either by coughing, glottic closure 
or equipment problems. 
2. The starting of the test should be satisfactory without hesitation. 
3. The exhalation time should be satisfactory with 6 seconds of smooth 
continuous exhalation and a plateau in the time volume curve of  atleast  
1 second . 
Criteria for reproducibility after getting 3 acceptable spirograms are: 
1. Largest FVC within 200 ml of next largest FVC. 
2. Largest FEV1within 200 ml of next largest FEV1. 
If these above two criteria are not met, then additional spirograms have to be 
performed. To meet the acceptability and reproducibility criteria maximum 
eight efforts can be allowed.  After eight efforts fatigue plays an important 
role in the results and interpretation which may not be reliable. If all the 
above criteria are not met, we should interpret the abnormal results with 
caution. 
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TECHNIQUE OF PERFORMING PULMONARY FUNCTION TESTS: 
1. The patient should be advised not to smoke atleast one hour before doing 
the test. 
2. The patient should be advised not to eat a heavy meal two hours before 
doing the test. 
3. The patient should be advised not to wear tight clothes as this may lead on 
to false results. 
4. False teeth if any, can be left in place unless these prevent the patient from 
forming an effective seal around the mouth piece. 
5. The patient should be well seated with the nose clip in place. 
6. It is necessary for the patient to practice the exercise before actually 
performing the test. The patient is asked to breathe in and out deeply several 
times. 
7. The patient should keep their mouth completely over the mouth piece but 
not inside it. 
8. The patient should be asked to blow out as fast and as quick as they can for 
atleast six seconds. 
9. Once the patient has blown out as much as they can ,ask the patient to 
inhale deeply as much as they can. 
10. The whole test can be repeated upto three times. The goal is to get a 
reproducible result that is consistent. 
30 
 
In order to get a  internally valid test, the patient may be asked to repeat the 
test more than three times. 
PHYSIOLOGICAL FACTORS AFFECTING PULMONARY FUNCTION 
TESTS: 
Spirometry can be reported as both absolute values and as percentage 
predicted values of the normal.  Standards for normality are based on the 
factors such as age, sex, height, weight and race with an abnormal value 
occurring if there is 20% difference from the predicted mean value. 
AGE: 
      As age progresses, the natural elasticity of the lung is reduced resulting 
in gradual decrease of lung volumes and lung capacities. 
GENDER: 
              In males, lung volumes and capacities are more when compared to 
females. Because of this gender difference, different normal tables should be 
used for males and females. 
BODY HEIGHT AND WEIGHT:    
                  Individuals with short stature will have smaller PFT result when 
compared to the tall individuals. Obese individuals in whom there is  
increased body fat to lean body mass ratio,  the abdominal mass prevents 
downward movement of the diaphragm resulting in smaller PFT than the 
expected. 
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RACE: 
PFTs of Caucasians are different from those of Blacks, Hispanics and Native 
Americans. 
TESTS OF VENTILATORY FUNCTION: 
BEDSIDE PULMONARY FUNCTION TESTS: 
1. COUGH TEST: 
       The patient is asked to take a deep inspiration and cough once. The test 
is positive if the first cough leads to recurrent coughing. This is suggestive 
of underlying bronchitis. 
2. WHEEZE TEST: 
        The patient is asked to take five deep breaths and then auscultated 
posteriorly between the shoulder blades to test for the presence or absence 
of wheezing. 
3. MAXIMUM LARYNGEAL HEIGHT: 
        The distance between the tip of the thyroid cartilage and the 
suprasternal notch at the end of expiration is measured. If this is <4cm, it is 
abnormal. It is an accurate sign of obstructive airway disease. 
4. FORCED EXPIRATORY TIME: 
        The bell of the stethoscope is placed over the trachea in the 
suprasternal notch and the stopwatch is set to zero. The patient is instructed 
to take in the deepest breath possible and then to blow it out as fast as 
possible as he could. When the patient begins to exhale, start the stopwatch 
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and stop it immediately as audible expiration is no longer heard. Value 
more than 6 seconds indicates severe expiratory airflow obstruction with 
%FEV1<50%.  The test is done three times and the average is taken. This 
clinically measured test correlates well with the forced expiratory time 
measured by spirometry. 
5. BREATH HOLDING TIME: 
        The patient is asked to take a deep breath and hold his breath as long as 
possible. The stethoscope is placed over the trachea to identify early 
expiration. A breath holding time of >30 seconds is normal.  Values 
between 20 -30 seconds denotes compromised cardiopulmonary reserve. 
The value <20 seconds denotes very poor cardiopulmonary reserve. 
6. SNIDER’S MATCH BLOWING TEST: 
         Patient’s maximum breathing capacity (MBC) can be measured by 
this test. A lighted match stick is placed at varying distances from the 
patient’s mouth. The patient is instructed to sit, to keep his mouth open and 
to blow the candle off without pursing the lips. The ability of the patient to 
blow the candle off at a distance of 22cm from the mouth indicates MBC 
>150L/min. Patients with moderate to severe COPD will find it difficult 
with this test. When there is need for oxygen therapy in COPD patients, this 
test is contraindicated. 
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7. SINGLE BREATH COUNTING TEST: 
         Ask the patient to count out loud numbers from 1 onwards after a 
maximum inspiration. Individuals who are able to count 50 or more have 
normal respiratory function. If the single breath count is <15, it indicates 
severe impairment of vital capacity. 
STATIC TESTS: 
        The static tests includes lung volumes and capacities.  The static lung 
volumes reflect the elastic properties of the lungs and the chest wall. 
        Lung volumes that cannot be measured by spirometry are Residual 
Volume, Total Lung Capacity and Functional Residual Capacity. 
TIDAL VOLUME (TV): 
         It is the volume of air that is inhaled or exhaled with each breath when a 
person is breathing at rest. 
INSPIRATORY RESERVE VOLUME (IRV): 
        It is the maximum volume of air that can be inhaled from the end of 
inspiration. 
EXPIRATORY RESERVE VOLUME (ERV): 
       It is the maximum volume of air that can be exhaled from the end of 
expiration. 
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INSPIRATORY CAPACITY (IC): 
      It is the maximum volume of air that can be inhaled from tidal volume end 
expiratory level. Inspiratory capacity is Inspiratory Reserve Volume plus Tidal 
volume. 
FUNCTIONAL RESIDUAL CAPACITY (FRC): 
It is the volume of air in the lungs that follows the exhalation of a tidal 
volume. It is expressed as the sum of ERV+RV. It is the lung volume at which 
the inward elastic recoil of the lungs is balanced by the outward elastic force of 
the relaxed chest wall. Usually FRC is 40-50% of the Total Lung Capacity. 
FRC increases when the lung elasticity is reduced and decreases when the lung 
recoiling is increased. Posture also influences the Functional Residual Capacity. 
In standing position FRC is more when compared to the supine position. This is 
one of the reason why patients in the postoperative recovery should be kept in 
the head elevated position. Almost all the anesthetic drugs reduces the muscle 
tone thereby reducing the FRC close to the residual volume in awake state. This 
is the cause for sudden desaturation  in case of obese patients, pregnant patients 
and patients with large intra-abdominal mass who are under anesthesia. Because 
of the loss of elastic lung tissue, FRC increases with age. The preoxygenation 
done prior to the induction of anesthesia is to replace the functional residual 
capacity with 100% oxygen that helps in delaying the desaturation of apneic 
patient during intubation. 
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CLOSING CAPACITY (CC): 
           Closing capacity is the lung volume at which the smaller airways in the 
dependent part of the lung begins to close.  Closing capacity is expressed as the 
sum of closing volume plus residual volume.CC=CV+RV.  Closing volume is 
the volume of gas that is expelled during phase 4 of the single breath nitrogen 
test. It denotes the lung volume from the starting of airway closure to the end of 
maximum expiration. Closing capacity in a normal young healthy adult is 
approximately 10% of vital capacity or 400-500 ml. 
            Closing volume and closing capacity increases as age increases.  In 
patients with small airway diseases and in chronic smokers,  the closing volume 
is increased.  The normal value of closing capacity is intimately related to age 
and position of the patient in patients with normal lung. The lowest value of 
closing capacity is usually seen in late 50s . Closing capacity is progressively 
increased above and below this age. The factors influencing the closing capacity 
are obesity, early chronic bronchitis, heavy smoking, left ventricular failure, 
myocardial infarction and immediate postoperative period. 
          FRC is either independent of age in adults or may increase very 
minimally with increasing age. But closing capacity increases as the age 
increases.  At the age of 66, closing capacity becomes equal to Functional 
residual capacity in upright position.  In the supine position, at the age of 44, 
CC becomes equal to that of FRC. FRC is influenced mainly by postural 
changes. When the patient is changed from supine to upright position there is 
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30% change in FRC.  On the other hand, CC is independent of body position. 
Therefore, to conclude FRC is dependent on posture and CC is dependent on 
age. FRC is decreased by approximately 20% with spontaneous ventilation and 
about 16% with artificial ventilation when the patient is anesthetised. After 
inducing the patient, a decrease in the cross sectional area of the rib cage occurs 
corresponding to decrease in the lung volume of about 200ml. In the dependent 
position, there will be cephalad movement of diaphragm. Previously it was 
thought that CC was unchanged during anesthesia but recent studies confirmed 
there is parallel decrease in CC along with FRC during anesthesia.  The use of 
positive end expiratory pressure may be the probable reason why there is 
increase in normal PO2 by increasing FRC above CC. 
            Closing capacity can be measured by single breath nitrogen washout 
technique.  This test was originally described by Flower in the year 1949. In this 
technique, the patient is instructed to slowly exhale to residual volume and then 
asked to slowly inhale a single breath of oxygen to maximum inhalation. Then 
the patient is asked to hold the breath for few seconds and then asked to exhale 
slowly and evenly. The volume of expired air and the instantaneous nitrogen 
concentration are recorded during this phase. A characteristic curve is obtained 
and this is called as single breath nitrogen curve. This curve consists of 4 
phases. 
Phase 1 – dead space gas. 
Phase 2 – Mixed dead space gas plus alveolar gas. 
37 
 
Phase 3 – Mixed alveolar gas from all the alveoli. 
Phase 4 – is the phase where there is sudden increase in nitrogen 
concentration. Closing capacity is the volume at which phase 4 begins. During 
inspiration the oxygen is distributed to the smaller alveoli in the dependent 
parts of the lung because of the shape of the alveolar compliance curve. This 
results in larger change in the volume of smaller alveoli than the larger alveoli. 
This is the reason for more dilution of nitrogen in the smaller alveoli. During 
expiration, the mixed alveolar concentration from all the alveoli is measured 
till a point where closure of airway begins. This is the point where there is 
increased nitrogen concentration because the expulsion of gases from the 
smaller airway stops and exhalation continues from the areas of lungs where 
there is increased nitrogen concentration. Closing volume and closing capacity 
can also be measured by Bolus technique with an inert tracer gas such as 
helium, xenon or argon.  
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  SINGLE BREATH NITROGEN CURVE  
 
 
FORCED VITAL CAPACITY (FVC): 
It is the total volume of air that can be forcibly exhaled from a maximum 
inspiratory effort. 
VITAL CAPACITY (VC): 
      It is the maximum volume of air that can be exhaled from the beginning of 
maximum inspiration.  Vital capacity is an important preoperative assessment 
tool because it reflects the ability of the patient to cough, to take a deep breath 
and to clear the excess secretion in the airways. Vital capacity is normally 
measured as 70 ml/kg ideal body weight. When the vital capacity is 
significantly reduced to <20ml/kg of the ideal body weight, it indicates that the 
patient is at increased risk for postoperative complications. Vital capacity helps 
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in evaluating the condition of the patient for weaning from a ventilator. If a 
patient who is on ventilator can demonstrate a vital capacity of 10-15 ml/kg of 
body weight, then it is generally considered that there is enough ventilatory  
reserve  to try for weaning and extubation. 
SLOW VITAL CAPACITY (SVC) TEST: 
             In this test, the patient is asked to blow out slowly and completely all 
the air from the lungs.  The advantage of this test is that it eliminates the strong 
bronchoconstriction  which usually accompanies  a strong forceful exhalation 
effort. Therefore, after a SVC test the vital capacity of the patient may be much 
larger because there is little or no airway collapse during a controlled and slow 
exhalation effort. If after performing a SVC test, the vital capacity is increased,   
then it is assumed that the original small FVC is caused by the collapse of the 
airways and it rules out the presence of restrictive airway disease. The 
restrictive pathology has to be considered if the vital capacity does not improve 
either with the inhalation of a bronchodilator or with the administration of a 
SVC test. 
TOTAL LUNG CAPACITY (TLC): 
      It is the total volume of air in the lungs at full inspiration. It is expressed as 
the sum of IC+FRC. 
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RESIDUAL VOLUME (RV): 
       Residual volume is the amount of air that is remaining in the lungs at the 
end of forceful expiration. Residual volume depends on two important factors- 
smaller airway collapse and limits of chest wall excursion.  Residual volume is 
determined by the compression of the chest wall by the muscles in case of 
restrictive lung pathologies. In case of obstructive lung diseases, Residual 
volume is influenced by the collapse of the terminal airways which prevents the 
distal air from escaping the lungs. 
METHODS TO MEASURE RESIDUAL LUNG VOLUME: 
1. NITROGEN WASHOUT TECHNIQUE: 
It is an open circuit gas dilution technique for measuring the Residual 
volume. In this technique, the patient breathes 100% oxygen at the end of a 
normal expiration and all the nitrogen in the lung is washed out. The exhaled 
volume and the concentration of nitrogen in that volume are measured. The 
difference in the volume of nitrogen at the initial concentration and at the final 
exhaled concentration allows to calculate the intrathoracic volume usually 
Functional Residual Capacity. 
2. HELIUM DILUTION TECHNIQUE: 
It is a closed circuit technique .It is based on the principle of inhalation 
of a known concentration and volume of an inert trace gas, such as helium, 
which is followed by equilibration of 7 to 10 minutes in the closed circuit. The 
concentration of helium which is finally exhaled is diluted in proportion to the 
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unknown volume of air in the patient’s chest. Usually, the patient is connected 
to the spirometer at the end tidal position and therefore the lung volume which 
is measured is Functional Residual Capacity. 
3. BODY PLETHYSMOGRAPHY: 
It is based on the principle of Boyle’s Law which states that the volume 
of gas at a constant temperature varies inversely with the pressure applied to it.  
In this technique, the patient is asked to sit in a closed “body box” with a known 
volume. The lung volumes are calculated based on the amount of air which is 
displaced from the box during ventilation. 
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                                          PAPPENHEIMER’S CURVE 
 
 
DYNAMIC TESTS: 
The parameters that can be recorded by spirometry are: 
1. FORCED EXPIRATORY VOLUME IN 1 SECOND(FEV1): 
  It is the volume of air forcibly expired from a maximum inspiratory  
effort in one second. The normal value is 80-120% of the predicted. 
2. FORCED VITAL CAPACITY(FVC): 
It is the total amount of air a person can exhale, usually measured in 6 
seconds. The normal value is 80-120% of the predicted. 70-80% demonstrates 
mild reduction. 50-70% demonstrates moderate reduction. Less than 50% 
demonstrates severe reduction. 
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3. TIMED FEV1/FVC: 
This provides an even better indication of degree of obstruction of the 
airway. This decreases the variability between the individuals and helps in the 
comparison between the individuals. This ratio is conventionally measured at 
0.5, 1 and 3 seconds. This test is used for the confirmation of chronic 
obstructive airway disease. 
4. FEV0.5/FVC: 
 It is used to assess the airflow at larger lung volumes and from the larger 
airways. Normally, it is >50%. 
5. FEV1/FVC RATIO: 
It is the percentage of FVC that can be expired in one second. 75-80% is 
normal. 60-80% demonstrates mild reduction. 50-60% demonstrates moderate 
reduction. Less than 50% demonstrates severe obstruction. FEV1/FVC is the 
most sensitive indicator of airflow obstruction than FEV1 alone. This ratio is 
less than 75% in case of obstructive lung diseases and it falls linearly with the 
progression of obstruction. FEV1/FVC reduces the variability and allows for 
more consistent results in assessing the dynamic airflow. 
6. FEV3/FVC: 
 It is used to assess the function of small airways. Normally, it is >95%. 
7. FORCED EXPIRATORY FLOW 200-1200: 
This measures over one litre of initial part of the spirogram.  This 
measurement starts at 200 ml to permit for the attainment of peak flow. This is 
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also known as Maximum Expiratory Flow Rate. Actually, this flow is lower 
than the true peak flow. Due to effort dependence, it has high variability. It is 
not useful for the assessment of small and medium sized airways or the 
response to treatment. The value <200litres/min in patients undergoing surgery 
suggests impaired cough efficiency and there is high chances for postoperative 
complications. This test provides a valuable tool in identifying gross pulmonary 
disability at the bedside because it is more pleasant and less exhaustive than 
FVC. 
8. FEF25%-75%: 
It is also known as Maximum mid-expiratory flow rate (MMEFR). It 
measures airflows over mid-half of vital capacity.  It is a sensitive indicator of 
early small airway dysfunction. The normal value is 4-5 litres/sec. More than 
80% is normal. 60-80% reflects mild obstruction in the small airways. 40-60% 
reflects moderate obstruction. Less than 40% reflects severe obstruction. This is 
effort independent, but it can be decreased by marked reduction in the 
expiratory effort and also by a subnormal inspiration before performing the 
maneuver. 
It is a highly variable spirometric index as it depends on the absolute 
volume of FVC and on the changes of airway obstruction. In the detection of 
mild abnormalities of lung dysfunction, the lung volumes such as TLC, FVC, 
FEV1 are all reduced and here FEF25%-75% does not appear to be more 
sensitive than FEV1. 
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DIFFERENCE BETWEEN FEV1 AND FEF25%-75%: 
         It is the volume of air forcibly expired from a maximum inspiratory effort 
in the first second. FEF25%-75% is the average flow in the middle half portion 
of forceful expiration, starting when 25% of FVC is exhaled and ending when 
75% FVC is completed. Even though both the values are decreased in 
obstructive airway diseases, FEF25%-75% reflects the calibre of airways <2mm 
in diameter as it is measured at lower lung volumes.  The flow becomes effort 
independent when the lung volumes are less than approximately 70% of FVC. 
This effort independence is attributed to equal pressure point concept. During 
forceful expiration, airway pressure gradually decreases as air moves from the 
distal most part of the airways to the proximal airway as the diameter of the 
airway increases and the corresponding resistance decreases. At a particular 
point in the distal airways, the intraluminal pressure falls below the external 
pressure compressing the airways which includes the pleural pressure and the 
lung recoil pressure, thereby the airway collapses trapping the air. When the   
expiratory effort that is the pleural pressure is greater, the equal pressure point is 
more proximal.  However the airway occlusion interrupts the airflow, the 
intraluminal pressure increases due to trapped air and reopens the airway. Thus, 
at equal pressure point, airflow is directly proportional to the elastic recoil of the 
lungs and inversely proportional to the resistance of the airways between alveoli 
and equal pressure point and not on the pleural pressure. 
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FORCED EXPIRATORY FLOW 75%-80%: 
                It is also known as Maximum end expiratory flow rate(MEEFR). It 
helps to assess the function of airways at lower lung volumes and is a sensitive 
indicator of small airway obstruction. 
FORCED INSPIRATORY FLOW (FIF): 
     FIF is usually measured using forced spirogram and also from the flow 
volume loop. As it is effort dependent, it is not a useful measurement. FIF is 
decreased in patients with neuromuscular diseases like myasthenia gravis. 
PEAK EXPIRATORY FLOW RATE (PEFR): 
  It is the maximum flow rate that is achieved by an individual during 
forced vital capacity maneuver, starting after full inspiration and ending with 
maximal expiration. PEFR depends on the airway caliber, patient’s effort and 
vital capacity of the patient. PERF is measured in lit/sec or lit/min. This is 
measured by either pneumotachography or by a specially designed instrument 
such as Wright’s peak flowmeter. The normal value of PEFR in males is 450-
700 ml/min and in females it is 300-500ml/min. 
CLINICAL APPLICATIONS OF PEFR: 
1. Measurment of PEFR 3-4 times/day and a variability of >15% is highly 
suggestive of bronchial asthma. Thus, it helps in the diagnosis and 
assessment of pulmonary status of bronchial asthma at home itself. 
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2. It helps to assess the reversibility. PEFR is measured before and after giving 
bronchodilator therapy. An increase in the value of 10-15% suggests 
significant reversibility of the condition. 
3. PEFR is used to measure exercise induced bronchospasm. PEFR is measured 
at rest and at 2 minutes interval during 6 minute exercise and a decrease in 
>15% is considered to be significant. 
4. It is used to assess the severity of pulmonary disease and effectiveness of 
therapy. 
5. PEFR is used to assess the circadian variation of the bronchial tree. 
6. It is also used to monitor the response to therapy and to follow up the course 
of the disease. 
Ideally, PEFR measurement is done twice daily. When it is done once daily, 
then it should be done consistently at the same time before and after 
bronchodilator therapy. There is high variation between the individuals and 
so it should be measured objectively based on the patient’s personal best 
conditions.  The personal best condition is the highest PEFR achieved in the 
middle of the day after bronchodilatation. 
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MAXIMUM BREATHING CAPACITY (MBC): 
The largest volume that can be breathed per minute by voluntary efforts is 
the maximum breathing capacity.  This is also known as Maximum Voluntary 
Ventilation (MVV). It estimates the peak ventilation available to meet the 
physiological demands. The patient is instructed to breathe as deep and as quick 
as possible for 12 seconds and the measured volume is multiplied by 5 to get the 
volume in one minute. MBC is expressed as litres/minute. The normal value is 
150-175 litres/minute. When the value is <75% of predicted, it is significant. 
It reflects the respiratory muscle status, compliance of thorax –lungs 
complex and airway resistance. 
It is the quick and easiest way to assess the strength of patient’s 
pulmonary musculature.  Poor performance of this test prior to surgery suggests 
that the patient may have pulmonary problems postoperatively due to muscle 
weakness. Since it parallels the FEV1, it can be used to test the internal 
consistency and to estimate patient cooperation. When the patient does not 
perform this test properly, the test becomes effort dependent. In this situation, it 
cannot be used to assess the true pulmonary muscle strength and compliance. If 
the value is disproportionately low in a patient who seems to be cooperating, 
one has to suspect for neuromuscular weakness. Most patients can generate 
fairly good single breathe efforts except in advanced neuromuscular diseases. 
Because MVV is much more demanding, it reveals decreased reserves of weak   
respiratory muscles. In pulmonary disorders like obstructive, restrictive 
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disorders or in patients with heart diseases and in very frail patients, low MVV 
can occur. 
FLOW VOLUME LOOPS: 
It is one of the way for determining the dynamic lung function by 
performing forced expiratory maneuver and plotting volume against flow.  The 
change in flow volume loops of various pulmonary disorders   can be predicted 
by this plot. Both flow and volume are plotted simultaneously on  X  and  Y 
recorder  when the patient fully inspires to Total lung capacity and then perform 
FVC maneuver.   
This is followed immediately by a maximum inspiration as quick as 
possible back to Total lung capacity. Normally at the beginning of forced 
expiration, the flow rate quickly raises to a peak value at a lung volume near 
Total lung capacity. As expiration continues, the lung volume decreases, airway 
becomes narrow, resistance increases and the flow rate becomes progressively 
decreased. The whole inspiratory portion of the loop and expiratory cycle near 
TLC is highly effort dependent but the expiratory flow at 75%-25%of vital 
capacity is effort independent. Normally, the expiratory to inspiratory flow ratio 
at 50% of vital capacity is about 1.0. This ratio becomes particularly important 
in the identification of presence of upper airway obstruction.  
It also helps to locate the site and to identify the nature of obstruction. 
There is no significant change in the diameter of the airways during inspiration 
or expiration. This results in a plateau of constant flow in the expiratory flow 
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over the effort dependent portion of vital capacity. There is similar plateau seen 
during the inspiratory flow also. As both are reduced to nearly the same extent, 
the mid vital capacity ratio remains approximately 1.0.   
A variable obstruction is defined as a lesion whose influence changes 
with the phase of respiration.  Variable extrathoracic obstruction occurs in case 
of single vocal cord paralysis, tracheomalacia or tumors invading the trachea.  
When a single vocal cord is paralysed, there is passive movement of this cord in 
accordance with the pressure gradient across the glottis. During a forceful 
inspiration, the paralysed vocal cord is drawn inwards resulting in reduced 
inspiratory flow. During a forced expiration, the paralysed vocal cord is blown 
aside. This results in unimpaired expired flow i.e. MIF50% FVC is <MEF 50% 
FVC. During normal inspiration, the airways inside the thorax becomes dilated 
as the lung inflates but the airways outside the thorax becomes collapsed due to 
negative intraluminal pressure.  
During expiration, the reverse happens as the airways inside the thorax 
becomes closed but the airways outside the thorax are held open by expiratory 
flow. As a result of this, variable extrathoracic obstruction leads to a flattened 
inspiratory limb with normal expiratory portion. 
Variable intrathoracic obstruction occurs in cases of distal tracheomalacia 
and bronchomalacia.  In this case, negative pleural pressure holds the floppy 
trachea open during a forceful inspiration.  During forced expiration, there is 
loss of structural support resulting in narrowing of the trachea and a plateau of 
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decreased flow.  There will be a brief period of maintained flow seen before the 
airway compression occurs. Therefore, a variable intrathoracic obstruction 
affects the expiratory limb mainly giving a flattened appearance of the 
expiratory portion of the loop. 
Fixed upper airway obstruction is seen in bilateral vocal cord paralysis, 
goitre and tracheal stenosis. Here, the flow is limited by the narrowed segment 
rather than by the dynamic compression of the airways. This results in the equal 
reduction of inspiratory and expiratory flow rates.  Therefore, both the top and 
bottom of the loop becomes flattened   resulting in the rectangular configuration 
of the loop.  
Hence, in case of fixed airflow obstruction  the airflow limitation 
becomes equal both during inspiration and expiration.(MEF=MIF). The 
advantages of flow volume loop is flow at a particular point can be easily read 
from the curve. The adequacy of patients effort can be easily known from the 
overall shape of the curve .when the expiratory effort is smaller, with a long 
concave shape of the curve, it indicates small airway obstruction. In case of 
large airway obstruction the peak flow rates are typically affected resulting in 
the flat flow volume loop. The flattening occurs either in the expiratory limb or 
inspiratory limb or both which depends on the site of obstruction. 
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DIFFUSION CAPACITY (DL): 
Diffusion capacity of the lung is defined as the rate at which a gas enters 
the blood divided by its driving pressure. The driving pressure is the gradient. 
The factors on which the diffusion capacity depends on are the character of the 
alveolar capillary membrane, effective surface area of gas exchange, volume of 
blood in alveolar capillaries, rate of combination of gas with blood and cardiac 
output. Diffusion capacity is also influenced by the thickness of alveolar 
capillary membrane.  The measurement of this provides information about the 
amount of functional capillaries which are in contact with ventilated air spaces. 
The gas which is used for the measurement of diffusion capacity is carbon 
monoxide. It has 200 times more affinity for haemoglobin than oxygen `and 
therefore it does not build up rapidly in plasma. Under normal conditions the 
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carbon monoxide concentration in the blood is low. Pulmonary capillary tension 
can be assumed to be zero. 
DLCO is the measurement of the ease of the transfer of CO molecules 
from alveolar gas to the haemoglobin of the red blood cells in the pulmonary 
circulation. It is also known as the transfer factor of carbon monoxide, which 
describes the process more accurately. It is a measure of the interaction of 
alveolar surface area, alveolar capillary perfusion, the physical properties of the 
alveolar capillary interface,  capillary volume, haemoglobin concentration, and 
the reaction rate of carbon monoxide and haemoglobin.  
The total diffusing capacity of the whole lung is the sum of the diffusing 
capacity of the pulmonary membrane component and the capacity of pulmonary 
capillary blood volume. DLCO – It is the capacity of the lungs to transfer 
carbon monoxide (ml/min/mmHg). DLCOc – It is the DLCO corrected for 
haemoglobin in ml/min/mmHg. DLVA – It is the DLCO corrected for volume 
in ml/min/mm Hg/lit. DLVC – It is the DLCO corrected for both volume and 
haemoglobin in ml/min/mm Hg/lit. 
          As haemoglobin concentration is a very important measurement in the 
interpretation of DLCO, in anemic patients DLCO may be decreased.  
The level of haemoglobin present in the blood and diffusing capacity are 
directly related.  Because of this, correction for anemic patients is used to 
further delineate whether a DLCO is reduced due to anemia or due to 
parenchymal or interface limitation. Reduction in the diffusing capacity can be 
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classified as mild, moderate and severe. When the reduction is less than the 
lower limit of normal but greater than 60% predicted, it is classified as mild.  
When the reduction is between 40% and 60% of the predicted value, it is 
classified as moderate. When the reduction is <40%, it is severe.  
          Different methods used for measuring DLCO are Steady state method and 
Single breath technique. The most commonly performed and standardised 
technique is Single breath technique. In this test, the patient inhales a known 
volume of test gas that contains 10% helium, 0.3% carbon monoxide, 21% 
oxygen and the remaining is nitrogen.  The patient is asked to inhale the test gas 
and holds breath for 10 seconds. Then the patient is asked to exhale to wash out 
a conservative overestimate of mechanical ad anatomical dead space. After this, 
an alveolar sample is collected. From the total lung volume, breath holding time 
and the initial and final alveolar concentrations of carbon monoxide, DLCO is 
calculated.  
The exhaled helium concentration is used for the calculation of single 
breath estimate of total lung capacity and the initial alveolar concentration of 
carbon monoxide.  The patients are instructed to avoid smoking for several 
hours before doing the test. The patients are also instructed not to consume 
alcoholic beverages for atleast 8 hrs prior to the test because alcohol vapours 
can affect the accuracy of some fuel cell types of carbon monoxide analysers. 
Normal DLCO at rest is 20-30 ml/min/mm Hg. It depends upon the lung size 
and is a measure of lung surface area available for gas exchange. When the 
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patient is unable to follow the instructions, it is a contraindication to do this test. 
Patients should be alert, oriented and they should be able to exhale completely 
and inhale to total lung capacity. They should be able to maintain an airtight 
seal on a mouthpiece and should be able to hold a large breath for 10 seconds. 
       Decrease in DLCO is seen in obstructive lung diseases like emphysema, 
cystic fibrosis. It is also decreased in parenchymal lung diseases like interstitial 
lung diseases caused by fibrogenic dusts like asbestosis, biologic dusts like 
allergic alveolitis, drug reactions like amiodarone, bleomycin and in sarcoidosis. 
DLCO may also be decreased in cases of systemic lupus erythematosus, 
progressive systemic sclerosis, mixed connective tissue diseases, Rheumatoid 
arthritis and in Wegener’s granulamatosis. It is also decreased in most of the 
cardiovascular diseases like acute myocardial infarction, mitral stenosis,   
pulmonary hypertension and pulmonary edema. Anemia, chronic renal failure, 
chronic hemodialysis , cigarette smoking and bronchitis obliterans organising 
pneumonia are some of the other diseases where there is decrease in DLCO. 
     Increase in DLCO is seen in diseases like polycythemia, pulmonary 
hemorrhage, left to right intracardiac shunts and exercise. 
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TEST FOR PULMONARY COMPLIANCE : 
          Compliance is defined as the change in volume per unit change in 
pressure. It includes three components: 
• Lung compliance is the change in lung volume per unit change in alveolar 
to intrathoracic pressure gradient. The normal value of lung compliance is 
200 ml/cm of H2O in the upright position. 
• Chest wall compliance is the change in lung volume per unit change in 
ambient to intrathoracic pressure gradient. The normal value of chest wall 
compliance is 200 ml/ sq.cm. 
• Total compliance is the change in lung volume per unit change in 
alveolar/ambient pressure gradient. The normal value of total lung 
compliance is 100 ml/ cm of H2O. The patient is asked to swallow a latex 
balloon in the esophagus and connected via a catheter to a pressure gradient 
and the total compliance is measured. The changes in esophageal pressure 
reflectsintrapleural pressure and change in lung volume is measured with a 
spirometer. 
TEST FOR PULMONARY RESISTANCE: 
It is the combination of airway resistance and pulmonary tissue 
resistance. 90% of the pulmonary tissue resistance is due to airway resistance 
(Raw). The airway resistance which is measured is used for the evaluation of 
airway obstruction. This technique is rapid and non invasive. The patient is 
asked to pant once or twice per second through a mouth piece and with the nose 
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clip in place. During a normal breathing, a major part of the resistance to 
airflow comes from the nose, pharynx and larynx.  The resistance offered by the 
nose is bypassed by using the mouth piece. The larynx is kept dilated by using 
the panting maneuver. It also reduces the total airflow resistance. 
The airway resistance is measured by asking the patient to sit in a 
constant volume body plethysmograph. This is done by recording the airflow at 
the mouth by means of pneumatachyograph and thereby simultaneously 
recording the transpulmonary pressure with latex balloon. The normal value of 
airway resistance is 0.5-2cm/sec. The airway resistance varies non-linearly with 
lung volume. The airway conductance (Gaw)  is the reciprocal of airway 
resistance . The airway conductance varies linearly with lung volume. Specific 
airway conductance is the ratio of airway conduction to lung volume. This is a 
highly reproducible measurement which signifies the caliber of the 
intrapulmonary airway. 
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DIABETES MELLITUS AND ANESTHESIA 
Diabetes mellitus is a systemic disease. It impairs many functions of the 
respiratory system by affecting the lungs. It reduces the lung elasticity, produces 
pulmonary microangiopathy and also affects the lungs with chronic 
inflammatory changes.  The lung volumes and diffusing capacity are decreased.  
In patients with autonomic neuropathy, hypoxic induced ventilator drive is 
reduced.  Due to the impaired chemoreceptor activity, diabetic individuals are 
more prone for the development of respiratory depression from drugs such as 
opioids and sedative agents. In diabetic patients the joints become stiff and 
rigid. The joints which are supporting the airway such as temporomandibular 
joint, atlanto-occipital joint and cervical joint may be involved resulting in 
difficulty in the management of airway.  This joint rigidity is thought to be 
caused by the non enzymatic glycosylation of proteins and abnormality in the 
cross linking of collagen in joints and also in other tissues. This results in 
difficulty in introducing the laryngoscopy and difficulty in intubating the 
patient. The rigidity of the joints can be tested by Prayer sign and Palm print 
test. The patient is asked to oppose the palms and fingers like doing in a prayer. 
The diabetic patients who are having stiff joints can have a positive test as they 
are not able to do this. The palm print test is used to test the rigidity of fourth 
and fifth interphalangeal joints. The palm and fingers of the dominant hand is 
painted with ink. Then the patient is asked to firmly press the hand on a white 
paper which is placed on a hard surface. 
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Diabetic autonomic neuropathy affects the cardiovascular system. It alters 
the compensatory mechanism which includes the baroreceptor reflexes.  This 
causes increased risk for hemodynamic lability. This hemodynamic alteration is 
produced mainly with the change of patient position, when positive pressure 
ventilation is given and when there is sympathetic blockade as in case of 
neuraxial blocks.  In this situation, the patient should be monitored very 
carefully. There should be meticulous maintainence of intravascular volume.  In 
these patients the loss of heart rate variability is a high risk factor for the 
development of ventricular arrhythmias and sudden death. There is high chance 
for the development of silent myocardial ischemia in diabetic patients with 
autonomic neuropathy. Respiratory arrest is also commonly seen in diabetic 
patients with autonomic neuropathy. 
The surgery poses many perioperative problems in diabetic patients.  The 
magnitude of stress response to surgery depends on the site of surgery, amount 
of tissue injured during the surgery.  The hormones such as catecholamines, 
cortisol and growth hormone are secreted in response to stress.These hormones 
alters the glucose homeostasis because they have anti-insulin and 
hyperglycaemic effects. The process such as glycogenolysis and 
gluconeogenesis are stimulated.  The peripheral uptake of glucose is decreased 
leading to hyperglycemia and ketosis. The magnitude of inflammation decides 
the increase in blood sugar during surgery. This results in excessive release of 
inflammatory cytokines, tumor necrosis factor, interleukin 1 and interleukin 6. 
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In addition to these factors, immobility itself is associated with decreased 
skeletal muscle sensitivity to insulin leading on to hyperglycemia. 
In fasting   patients who are undergoing elective major intra-abdominal 
surgeries, the blood glucose levels will increase between 126 and 180 mg/dl. In 
the case of cardiac surgeries, where there will be relatively more stress, the 
disturbance of glucose homeostasis is greater resulting in the rise of blood 
glucose above 270 mg/dl in patients who are not having diabetes. In patients 
with diabetes this value may go above 360mg/dl. The increased stress in 
diabetic patients may  results in the  development of diabetic crisis such as 
diabetic ketoacidosis or hyperglycaemic hyperosmolar coma. In case of 
gastrointestinal surgeries, there may be the need for the prolonged period of nil 
oral which means interruption of oral intake. This prolonged starvation can lead 
on to ketosis. Therefore there may be necessary for the perioperative   
administration of insulin for controlling the blood sugar.  When the patient 
returns to normal oral intake, the diabetic management can be reverted back to 
his presurgery protocol. 
Hypoglycemia poses a major problem in the perioperative period. The 
altered level of consciousness may mask the signs and symptoms of 
hypoglycaemia in the perioperative period.  The anesthesia and surgery is 
associated with circulatory disturbances. This   causes alteration in the 
absorption of subcutaneous insulin.Therefore,   administration of intravenous 
insulin is preferred in the perioperative period. 
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yperglycemia is also with associated with increased risk of complications 
such as wound infection, poor wound healing and poor neurological outcome in 
susceptible patients. Therefore, the goals for the management of diabetic 
patients in the perioperative period are minimal metabolic disruption, avoidance 
of untoward events and return to stable glycemic control as soon as possible. 
When hyperglycemia is left untreated, many adverse effects can occur. There 
may be chance for dehydration which results from the osmotic diuretic effect of 
glycosuria. Because of the accumulation of ketoacids and lactic acids, academia 
occurs. Untreated hyperglycemia can lead on to electrolyte imbalance such as 
potassium and magnesium. This electrolyte imbalance poses increased risk of 
arrhythmias. 
PRINCIPLES OF ANESTHETIC MANAGEMENT IN DIABETES 
MELLITUS: 
1. The diabetic patients are more prone for hypoglycaemia and ketosis because 
of overnight fasting. Therefore, one should give preference for the diabetic 
patients on the operating list. 
2. There may be chance for delayed gastric emptying in patients with diabetic 
autonomic neuropathy. There may be undiagnosed   gastroparesis which 
results in the prolonged retention of food in the stomach. This results in the 
increased risk for aspiration and regurgitation.  The preoperative use of oral 
erythromycin on gastric motility was proven to be effective. In diabetic 
patients, a 12 hour fasting before surgery may be beneficial. 
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3. The use of intravenous fluids should be meticulous in the diabetic patients in 
the perioperative period.  When Ringer’s lactate is given in larger volumes, 
the lactate undergoes gluconeogenesis in the liver and complicates the blood 
sugar control. When normal saline is used in larger volumes, it increases the 
risk of hyperchloremic acidosis.  Therefore there is no ideal solution for use 
in diabetic patients and  so any fluids we are using should be used 
judiciously. 
4. In the anesthetised patient, the measurement of blood glucose level should be 
done frequently, rapidly and accurately. This is because the need for glucose 
and insulin during this period is unpredictable and hypoglycemia may go 
undetected. 
5. Close monitoring should be done in diabetic patients during surgery. The 
standard monitors such as ECG, SPO2, BP, ETCO2 and temperature probe 
should be used. When there is presence of other comorbidities, other 
advanced monitorin can be used. 
6. The glycosylated haemoglobin ( HbA1c)  provides a valuable guide for the 
long term glycemic control during the preoperative check up. It has no role 
in the intra operative or in the postoperative period. 
7. In diabetic patients receiving longer acting insulin, there is high risk for 
hypoglycaemia in the perioperative period if glucose is not supplemented. 
Perioperative administration of glucose increases the postoperative glucose 
utilization rates. 
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8. Insulin supplementation may be needed in patients with absolute insulin 
deficiency and infections in the intraoperative period for the prevention of 
lipolysis and proteolysis which can lead on to ketosis. 
GENERAL ANESTHESIA AND DIABETES MELLITUS: 
INDUCTION: 
The choice of induction agent for general anesthesia in diabetic patients 
depends on the severity of associated systemic diseases which includes coronary 
artery disease, nephropathy, neuropathy and hypertension.  Supplementation of 
epidural analgesia may be beneficial after due consideration of autonomic 
neuropathy, peripheral neuropathy  and ischemic heart disease. But this should 
be avoided in patients with sepsis. When epidural analgesia is supplemented, 
the dose of opioid analgesics can be reduced thereby decreasing the side effects 
such as respiratory depression.  Epidural analgesia also helps to blunt the stress 
induced neurohormonal response. Rapid sequence induction should be 
performed in diabetic patients with gastrointestinal symptoms because of the 
risk of regurgitation and aspiration. In patients with anticipated difficult 
intubation, awake fibreoptic bronchoscopy would be the preferred technique. 
Patients should be carefully induced with Etomidate or Thiopentone sodium 
with high dose fentanyl and midazolam because in patients with autonomic 
neuropathy exaggerated hypotension is common.  In patients with extensive 
peripheral neuropathy Succinyl choline should be avoided due to the increased 
risk of potassium release in these patients. In the presence of renal dysfunction, 
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atracurium and mivacurium are the preferred muscle relaxants. In case of rapid 
sequence induction, rocuronium may be the preferred muscle relaxant. 
MAINTAINANCE OF ANESTHESIA: 
Anesthesia should be maintained with inhalational agents such as 
isoflurane or sevoflurane with an air oxygen mixture. Nitrous oxide can be used, 
but it should be avoided in patients with intestinal obstruction   due to the risk of 
bowel distension.  The patients with perforative peritonitis and sepsis should be 
put on postoperative elective ventilation to optimise their oxygen delivery.  
When the bowel is very distended and when the abdominal closure is very 
tense, there is need for postoperative elective ventilation. For this the airway 
pressures should be observed observed after the abdomen is closed.  In the less 
severe cases, the patient can be reversed and extubated at the end of surgery. 
Before extubation, the patient should have adequate recovery of airway reflexes. 
EFFECT OF ANESTHETIC DRUGS ON DIABETES MELLITUS: 
Ketamine causes significant hyperglycemia. Etomidate blocks the adrenal 
streroidogenesis  which results in the suppression of cortisol synthesis .This 
decreases the hyperglycaemic response to surgery in non diabetic patients. The 
effect of etomidate on diabetic patients have not been established yet. Diabetic 
patients have decreased ability for the clearance of lipids from the circulation. 
Therefore, in the intensive care unit, in diabetic patient who are receiving 
propofol for prolonged sedation, the dose should be adjusted. 
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The effect of inhalational agents such as halothane, enflurane, isoflurane 
and sevoflurane on blood sugar control  has only in vitro significance.  This 
invitro studies shows that the inhalational agents  inhibits the insulin response to 
glucose in a reversible and dose dependent manner. The effect of inhalational 
agents on blood glucose level in vivo has not yet established.  
The secretion of adrenocorticotrophic hormone (ACTH)  and cortisol are 
decreased when high dose of benzodiazepines are used. The benzodiazepines 
stimulates the secretion of growth hormone but reduces the sympathetic 
stimulation resulting in decreased glycemic response to surgery. When 
midazolam is given in usual sedative doses, these effects are minimal. 
When opioids are used in high doses, it produces hemodynamic, 
hormonal and metabolic stability. The high dose opioids block the entire 
sympathetic system and also the hypothalamic-pituitary axis effectively. This 
may be probably due to the direct effect of opioids on the hypothalamus and the 
higher centres. But it was found that midazolam and fentanyl, by reducing the 
glucose clearance results in hyperglycemia. 
Ganglion blocking agents which are used for hypotensive anesthesia can 
block the sympathetically mediated hepatic gluconeogenesis resulting in 
hypoglycemia.  When beta blockers are used, it results in slower recovery from 
hypoglycemia. 
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MANAGEMENT OF PERIOPERATIVE BLOOD SUGAR CONTROL: 
The aims of perioperative control of blood sugar are 
• To reduce mortality and morbidity. 
• To avoid hypoglycaemia. 
• To avoid hyperglycemia. 
• To avoid ketosis. 
Most of the problems happens when the blood glucose level 
is>180mgs%.  But in many patients, there is need for the maintainance of tight 
blood sugar control. Due to the fear of hypoglycaemia, the blood sugar is 
usually maintained in somewhat a higher range. But, now with the easy 
availability of bedside glucose tests and increasing risk of hyperglycemia, 
permissive hyperglycemia is no longer acceptable. Therefore, measurement of 
regular blood sugar is very important for the prevention of catastrophic events 
due to the extremes of blood glucose level. The blood sugar should be 
monitored prior to the induction of anesthesia and every hour thereafter when 
insulin infusions are used intraoperatively. 
The perioperative control of blood sugar depends on whether the patient 
is on meal plan alone or on oral hypoglycaemic agents or on insulin. It also 
depends on the type of surgery whether major or minor.  Patients whose blood 
glucose is well controlled with meal plan alone do not require any special 
perioperative intervention for the blood sugar control. In these patients, fasting 
blood sugar should be measured on the morning of surgery. If the surgery lasts 
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for more than 1 hour, intraoperative monitoring of blood glucose level is 
essential. In patients undergoing major surgeries and in patients with poorly 
controlled blood glucose level, an intravenous infusion of insulin and dextrose 
should be considered and here there is need for hourly monitoring of blood 
glucose level intraoperatively. In case of minor surgeries, no specific therapy is 
required. 
If the patient is on oral hypoglycaemic drugs like   sulfonylureas, it 
should be discontinued 1 day prior to surgery except Chlorpropamide , which 
should be stopped 2-3 days prior to surgery.  Metformin should be stopped 1-2 
days prior to surgery in case of sick patients.  
In case of minor surgeries, the patient should be asked to continue the 
usual diabetic treatment till night prior to surgery. The dose should be with hold 
on the morning of surgery. Dextrose containing solutions should be avoided.  
Blood glucose should be monitored intraoperatively and if needed the patient 
should be treated with dextrose insulin infusion. In diabetic patients, the oral 
intake should be restarted as early as possible postoperatively. In minor 
surgeries if there is perioperative hyperglycemia (200mg/dl) , it should be 
managed with  small subcutaneous dose of short acting insulin with frequent 
monitoring of the blood sugar level to avoid hypoglycemia. In case of major 
surgeries, the patient should be switch over to regular insulin if the patient is on 
OHAs. The optimal fasting blood sugar value preoperatively is 80- 120 mgs% 
for elective surgeries. If the patient is on long acting insulin it should be 
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switched over to a combination of short acting and intermediate acting insulins 
1-2 days before elective surgeries.  The blood glucose level should be 
monitored every hourly intraoperatively and immediately after surgery.  There 
should be 1 hour gap between the stoppage of intravenous insulin and the 
restarting of subcutaneous insulin.  If the diabetic patients who is on insulin are 
planned for elective major surgeries, the   patient should be admitted 2-3 days 
before surgery especially if the blood sugar control is suboptimal. The obligate 
glucose requirement for cells such as neurons and RBCs which uses only   
glucose as substrate is 2mg/kg/min. This can be provided by 5% or 10% 
dextrose containing solutions.  5% dextrose solution can be given at a rate of 
100-125 ml/hr. The initial insulin infusion rate can be calculated as between one 
half and three fourths  of the patient’s calculated hourly requirement which is 
patient’s daily dose divided by 24. The dose of insulin requirement is higher in 
septic patients, obese, critically ill, patients on steroids and in patients who are 
undergoing cardiopulmonary bypass surgery. 
The tight sugar control refers to maintaining blood sugar within a narrow 
range usually between 70-110 mgs%. But this approach has the significant risk 
of hypoglycaemia. The threshold above which complications increase is also 
not known.  The exact limit to maintain blood sugar levels for best outcome is 
not clearly documented.  In patients such as cardiac surgeries, neuronal injuries, 
burns, transplant surgeries, critically ill patients and pregnant patients the tight 
blood sugar control has beneficial effects. The adverse neurological outcome 
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due to hyperglycemia is due to intracellular acidosis and hypoxic neuronal 
edema.  Due to hyperglycemia, the stages of inflammation such as chemotaxis, 
phagocytosis,  polymorphonuclear  neutrophils adhesion and apoptosis are 
impaired leading to increase in the risk of infection. In cardiac surgeries, the 
risk of infection is higher in patients with poor postoperative blood sugar 
control both in diabetics and also in non diabetics.              
HYPERGLYCEMIC EMERGENCIES: 
This includes Diabetic ketoacidosis (DKA)  and Hyperglycemic 
Hyperosmolar State(HHS). The mechanism behind both these disorders is 
decrease in the action of circulating insulin along with increase in the counter 
regulatory hormones such as growth hormone, glucagon, catecholamines and 
cortisol. DKA is the condition where there is absolute deficiency of insulin 
whereas HHS is a condition with lesser degree of insulin deficiency. DKA is 
usually seen in type 1 diabetic patients. DKA can sometimes be the presenting 
feature of type 1 diabetes. In type 2 diabetic patients, DKA occurs during acute 
stress such as trauma, surgery and infection. Sometimes DKA occurs due to the 
discontinuation of antidiabetic treatment. It also occurs with the drugs that 
affects the carbohydrate metabolism. These drugs include steroids, thiazide 
diuretics, sympathomimetic drugs and some of the antipsychotic drugs.  DKA is 
a proinflammatory state. It produces reactive oxygen species, cytokines,C-
reactive protein and plasminogen activator inhibitor. 
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           The clinical features includes polyuria, polydipsia, symptoms of acidosis 
and dehydration which includes respiratory distress, tachycardia,  drowsiness, 
coma  and abdominal pain. Other symptoms like vomiting, malaise and cramps 
can occur. 
REGIONAL ANESTHESIA AND DIABETES MELLITUS 
The advantages of regional anesthesia in diabetic patients are: 
• Epidural anesthesia has minimal effect on the glucose metabolism when 
compared to general anesthesia.  In pelvic and lower limb surgeries, if the 
surgery is done under epidural anesthesia the levels of circulating glucose, 
catecholamines and cortisol are not increased. In low spinal anesthesia, the 
insulin response to a bolus of glucose is well preserved.  In case of high 
spinal level, due to sympathetic blockade the insulin secretion may be 
impaired.  However, there is no clear cut evidence that either regional 
anesthesia or general anesthesia can have beneficial effects in terms of 
major complications or mortality.  
• As the patient is awake in regional anesthesia , hypoglycaemia and 
hyperglycaemic coma can be easily detected. 
• Regional anesthesia allows early return of normal oral intake   and also 
early resumption of regular treatment regimen. 
• Regional anesthesia avoids the potential problem which occurs during 
laryngoscopy and tracheal intubation. 
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• It provides excellent analgesia. It avoids the use of systemic analgesics such 
as NSAIDs which produces dangerous effects in patients with diabetic 
nephropathy. Respiratory depression caused by opioid analgesics is also 
avoided. 
The disadvantages of regional anesthesia are: 
• There is high chance for the risk of nerve damage. In diabetic patients, if 
epinephrine is used in regional anesthesia, there is more chance for ischemic 
nerve damage. 
• Because of the persistence of vagal afferent input, epidural anesthesia may 
not be very effective in reducing stress response in case of upper abdominal 
and thoracic surgeries. 
• In diabetic patients with autonomic neuropathy, regional anesthesia carries a 
high risk. Severe hypotension can occur in autonomic neuropathy because 
of the compromised   cardiovascular compensatory mechanism. This 
produces deleterious effects in diabetic patients with associated 
comorbidities such as coronary artery disease, stroke and renovascular 
insufficiency. 
• In diabetic patients, the risk of infection and vascular damage are increased 
when regional anesthesia is used. 
• As diabetic patients are more prone for infections, epidural abscess can 
occur commonly following spinal and epidural anesthesia. 
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• Diabetic peripheral neuropathy which occurs after regional anesthesia may 
be confused with an anesthetic complication of nerve block. This results in 
medicolegal problems. 
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                              REVIEW OF LITERATURE 
1. LUNG INDIA/VOL 30/ ISSUE 2/ APR-JUN 2013: 
         A study was conducted on pulmonary function tests in type 2 diabetic 
patients and their association with glycemic control and diabetes duration. 
They found that the parameters FEV1, FVC, FEF25%, PEFR were 
decreased significantly in patients with diabetes except FEV1/FVC. They 
also found out that there was no correlation between pulmonary function 
tests and the duration of diabetes as well as HbA1c.  In this study, they 
concluded that diabetes mellitus which affects many systems, mainly affects 
lungs causing restrictive pattern of ventilatory changes. This may be due to 
the connective tissue glycosylation, decreased elastic recoiling and also due 
to inflammatory changes which occurs in the lungs. 
2. LUNG INDIA/ VOL 28/ ISSUE 2/ APR-JUN 2011: 
          A study was conducted between January to June 2004 in 128 individuals 
who were non smokers and who do not have any acute or chronic 
respiratory diseases. They found out that the individuals with diabetes 
showed a significant reduction in FEV1, FVC and SVC when compared to 
the non diabetic individuals. They also found out that there was no 
significant difference in the maximum mid expiratory flow and forced 
expiratory ratio between the two groups.  In this study, they also found out 
that there was a significantly increased level of triglycerides among the 
diabetic individuals. They concluded in this study that the diabetic patients 
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showed decreased lung function which is not dependent on smoking and it 
could be a chronic complication of diabetes mellitus. 
3. INDIAN J MED RES 119, FEBRUARY 2004, PP 66-71: 
         A study was conducted in 29 type 2 diabetic patients and 11 healthy 
control subjects. They divided these patients into 3 groups.  Group 1 
includes type 2 diabetic patients with microangiopathic complications 
which includes diabetic nephropathy, diabetic neuropathy or retinopathy. 
Group 2 includes type 2 diabetic patients who do not have any of the 
complications.  Group 3 includes non diabetic healthy control subjects. In 
this study, they did the pulmonary function test which includes strength of 
the respiratory muscles. They also studied the relationship between type 2 
diabetes mellitus with anthropometric measurement, glycemic control and 
microangiopathic changes.  In this study, they found out that there was a 
significant reduction in DLCO in type 2 diabetic patients who were 
complicated with microangiopathic changes. In this study, they also found 
out that there was no significant difference in FEV1, FVC, PEFR, 
maximum inspiratory and expiratory pressures among the 3 groups. They 
also found out that there was a significant correlation between DLCO and 
HbA1c, lipid profile and creatinine clearance in diabetic patients with 
microangiopathic changes. 
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4. INTERNATIONAL JOURNAL OF BIOMEDICAL AND ADVANCED 
RESEARCH(2012) 03 (08): 
               A study was conducted to evaluate the dynamic functions of the lung 
in individuals with type 2 diabetes mellitus. The dynamic functions of the 
lung such as PEFR , maximum expiratory pressure were recorded. In this 
study, they found out that PEFR and MEP were decreased in patients with 
type 2 diabetes mellitus when compared to the control group. They also 
found out that MEP shows a highly significant reduction. In this study, they 
concluded that the decrease in the dynamic functions of the lung in the 
study group is attributed to the respiratory muscle weakness. 
5. THE FREMANTLE DIABETES STUDY/ DIABETES CARE/ MARCH 
2004/ VOL 27: 
           A study was conducted to evaluate the relationship between diabetes 
mellitus, glycemic control and pulmonary function tests. They found out 
that airflow limitation and decreased lung volumes are mainly the chronic 
complications in patients with type 2 diabetes mellitus. They also found out 
that the severity of these complications was related to the glycemic 
exposure.  They found out in this study that, after ruling out other risk 
factors, airflow limitation is an independent predictor of death in patients 
with type 2 diabetes mellitus. 
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MATERIALS AND METHODS 
Study type                        : Interventional 
Design of study                :  Prospective case control study 
Selection of study subjects  :  cases posted for elective major abdominal       
      Surgeries.                                                                        
1. INCLUSION CRITERIA: 
Elective major abdominal surgeries (eg. Open cholecystectomy, gastric 
surgeries, pancreatic surgeries). 
Duration of surgery <4 hrs. 
Both sexes. 
Age 40-60 yrs. 
ASA 1 & 2 patients. 
Non smokers. 
 
2. EXCLUSION CRITERIA: 
 Patient refusal. 
Patients with  complaints of cough, sputum or dyspnoea. 
Patients with  cardio-respiratory diseases or any major illness. 
Duration of surgery > 4 hrs. 
Patient requiring mechanical ventilation after surgery. 
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METHODOLOGY: 
Fifty type 2 diabetic patients and fifty non- diabetic patients in the age 
group of 40-60 yrs undergoing elective major abdominal surgeries under 
General Anesthesia   were selected for the study. General Anesthesia was 
standardised for both the groups.  Pulmonary function tests were performed 60 
minutes before and 60 minutes after the end of surgery. In the diabetic group, 
patients with duration of diabetes of 5-15 yrs were selected for the study. 
Study group (diabetic group)  -  diabetic patients with duration of diabetes 
of 5-15 yrs  in the age group of 40-60 yrs  of both sexes undergoing elective 
major abdominal surgeries. 
Control group(non-diabetic group) – non diabetic patients in the age 
group of 40-60 yrs of both sexes undergoing elective major abdominal 
surgeries. 
The pulmonary function tests recorded were; 
1. Forced expiratory volume in 1 second (FEV1). 
2. Forced Vital Capacity (FVC). 
3. FEV1/FVC ratio. 
4. FEF 25%. 
5. Peak Expiratory Flow Rate (PEFR). 
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OBSERVATIONS AND RESULTS 
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square,‘t’ value and   'p'  values were calculated.  ‘t’  test was 
used to test the significance of difference between quantitative variables and  
Yate’s and Fisher’s chi square tests for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
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A: CHARACTERISTICS OF CASES STUDIED: 
Table A1: Age Distribution 
Age Group 
No of Cases in 
Diabetic Group Non Diabetic Group 
No % No % 
 41 45 yrs 6 12 7 14 
46 – 50 yrs 9 18 14 28 
51 – 55 yrs 17 34 16 32 
56 – 60 yrs 18 36 13 26 
Total 50 100 50 100 
Range 42 – 60yrs 42 – 60yrs 
Mean 52.9yrs 51.3 yrs 
SD 4.8yrs 4.8 yrs 
‘p’ 0.1036 Not significant 
 
The comparison of age group between diabetic group and non diabetic 
group shows that the ‘P’ value is 0.1036 which is not significant. 
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Table A2 : Sex Distribution 
Sex 
Diabetic Group Non Diabetic Group 
No % No % 
Male 26 52 28 56 
Female 24 48 22 44 
‘p’ 0.4206 Non Significant 
 
The comparison of sex distribution between diabetic group and non 
diabetic group shows that the ‘P’ value is 0.4206 which is not significant. 
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Table A4: Duration of  Surgery 
Group 
Duration of Surgery (minutes) 
Mean SD 
Diabetic Group 129.0 24.2 
Non Diabetic Group 132.6 20.9 
‘p’ 0.4286 Not Significant 
 
The comparison of duration of surgery between diabetic group and non 
diabetic group shows that the ‘P’ value is 0.4286 which is not significant. 
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TableA3 : Height / Weight / BMI 
Group 
Height (in cms) Weight ( in kgs) BMI 
Mean SD Mean SD Mean SD 
Diabetic Group 163.8 4.7 61.0 6.9 22.7 1.7 
Non Diabetic 
Group 
163.6 5.5 62.1 9.5 23.2 3.0 
‘p’ 
0.8455      
Not Significant 
0.5008  
Not Significant 
0.3109  
Not Significant 
 
The comparison of height, weight and BMI between diabetic group and 
non diabetic group shows that the ‘P’ values are 0.8455, 0.5008 and 0.3109 
respectively which are not significant. 
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B:  PRE OPERATIVE PULMONARY FUNCTION TEST VALUES IN 
DIABETIC AND NON DIABETIC PATIENTS 
Table B1:Preoperative FEV 1 
Group 
Pre Operative FEV 1 
 
Mean SD 
Diabetic Group 84.5 3.5 
Non Diabetic 
Group 
88.3 3.7 
‘p’ <0.0001 Significant 
 
The comparison of preoperative FEV1 in diabetic group and non diabetic 
group shows that the ‘P’ value is <0.0001 which is significant. 
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Table B2 :Preoperative FVC 
Group 
Pre Operative FVC 
 
Mean SD 
Diabetic Group 80.6 3.0 
Non Diabetic Group 82.4 2.6 
‘p’ 0.0017  Significant 
 
 
The comparison of preoperative FVC in diabetic group and non diabetic 
group shows that the ‘P’ value is 0.0017 which is significant. 
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Table B3 :Preoperative FEV1/FVC 
Group 
Pre OperativeFEV1/FVC 
Mean SD 
Diabetic Group 105.8 7.0 
Non Diabetic Group 107.2 4.4 
‘p’ 0.0513  Not Significant 
 
The comparison of preoperative FEV1/FVC in diabetic group and non 
diabetic group shows that the ‘P’ value is 0.0513 which is not significant. 
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Table B4:Preoperative FEF 25% 
Group 
Pre Operative FEF 25% 
Mean SD 
Diabetic Group 80.9 4.6 
Non Diabetic Group 83.4 4.1 
‘p’ <0.0053 Significant 
 
The comparison of preoperative FEF 25% in diabetic group and non 
diabetic group shows that the ‘P’ value is <0.0053 which is significant. 
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Table B5 :Preoperative PEFR 
Group 
Pre Operative PEFR 
Mean SD 
Diabetic Group 74.4 4.4 
Non Diabetic Group 77.1 6.8 
‘p’ 0.0199 Significant 
 
The comparison of preoperative PEFR in diabetic group and non diabetic 
group shows that the ‘P’ value is 0.0199 which is significant. 
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C :POST OPERATIVE PULMONARY FUNCTION TEST VALUES IN 
DIABETIC AND NON DIABETIC PATIENTS 
Table C1 :Postoperative FEV1 
Group 
Post operative FEV1 
Mean SD 
Diabetic Group 69.1 4.1 
Non Diabetic Group 86.6 3.6 
‘p’ <0.0001 Significant 
 
 
The comparison of postoperative FEV1 in diabetic group and non 
diabetic group shows that the ‘P’ value is <0.0001 which is significant. 
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Table C2 :Postoperative FVC 
Group 
Post operative FVC 
Mean SD 
Diabetic Group 63.1 4.6 
Non Diabetic Group 80.4 3.5 
‘p’ <0.0001 Significant 
 
The comparison of postoperative FVC in diabetic group and non diabetic 
group shows that the ‘P’ value is <0.0001 which is significant. 
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Table C3 :Postoperative FEV1/FVC 
Group 
Post operative FEV1/FVC 
Mean SD 
Diabetic Group 108.8 6.3 
Non Diabetic Group 107.8 4.9 
‘p’ 0.2699 Not Significant 
 
The comparison of postoperative FEV1/FVC in diabetic group and non 
diabetic group shows that the ‘P’ value is 0.2699 which is not significant. 
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Table C4 :Postoperative FEF 25% 
Group 
Post operative FEF 25% 
Mean SD 
Diabetic Group 62.6 4.3 
Non Diabetic Group 81.9 3.4 
‘p’ <0.0001 Significant 
 
The comparison of postoperative FEF 25% in diabetic group and non 
diabetic group shows that the ‘P’ value is <0.0001 which is significant. 
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Table C4:Postoperative PEFR 
Group 
Post operative PEFR 
Mean SD 
Diabetic Group 59.1 3.4 
Non Diabetic Group 76.3 5.6 
‘p’ <0.0001 Significant 
 
The comparison of postoperative PEFR in diabetic group and non 
diabetic group shows that the ‘P’ value is <0.0001 which is significant. 
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D:PRE OPERATIVE AND POST OPERATIVE PULMONARY 
FUNCTION TEST VALUES IN DIABETIC AND NON DIABETIC 
PATIENTS. 
Table D1 :Preoperative and Postoperative FEV1 
FEV1 Value 
Diabetic Patients Non Diabetic Patients 
Mean SD Mean SD 
Pre operative 84.5 3.5 88.3 3.7 
Post 
Operative 
69.1 4.1 86.6 3.7 
‘p’ <0.0001 Significant 0.0703 Not significant 
 
The comparison of preoperative and postoperative FEV1 in diabetic 
patients shows that the ‘P’ value is <0.0001 which is significant.  
The comparison of preoperative and postoperative FEV1 in non diabetic 
patients shows that the ‘P’ value is <0.0703 which is not significant. 
 
 
 
PRE OPERATIVE & 
POST  OPERATIVE  FEV1
84.5
88.3
86.6
80
85
90
95
100
M
e
a
n
 
v
a
lu
e
s
PRE OPERATIVE FEV1 POST OPERATIVE FEV1
69.1
60
65
70
75M
e
a
n
 
v
a
lu
e
s
DIABETIC
GROUP
NON
DIABETIC
GROUP
COMPARISON OF PREOPERATIVE AND 
POSTOPERATIVE FEV1 IN  DIABETIC GROUP  
AND NON DIABETIC GROUP
94 
 
Table D2 :Preoperative and Postoperative FVC 
FVC Value 
Diabetic Patients Non Diabetic Patients 
Mean SD Mean SD 
Pre operative 80.6 3.0 82.4 4.6 
Post Operative 63.1 4.6 80.4 3.5 
‘p’ <0.0001 Significant 0.1167 Not significant 
 
The comparison of preoperative and postoperative FVC in diabetic 
patients shows that the ‘P’ value is <0.0001 which is significant.  
 The comparison of preoperative and postoperative FVC in non diabetic 
patients shows that the ‘P’ value is <0.1167 which is not significant. 
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Table D3:Preoperative and Postoperative FEV1 / FVC 
FEV1 / FVC Value 
Diabetic Patients Non Diabetic Patients 
Mean SD Mean SD 
Pre operative 105.8 7.0 107.2 4.4 
Post Operative 108.8 6.3 107.8 3.0 
‘p’ 0.2946 Not significant 0.364 Not Significant 
 
The comparison of preoperative and postoperative FEV1/FVC in diabetic 
patients shows that the ‘P’ value is 0.2946 which is not significant.  
 The comparison of preoperative and postoperative FEV1/FVC in non 
diabetic patients shows that the ‘P’ value is 0.364 which is not significant. 
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Table D4: Preoperative and Postoperative FEF 25% 
FEF 25% Value 
Diabetic Patients Non Diabetic Patients 
Mean SD Mean SD 
Pre operative 80.9 4.6 83.4 4.1 
Post Operative 62.6 4.3 81.9 3.4 
‘p’ <0.0001 Significant 0.0584 Not significant 
 
The comparison of preoperative and postoperative FEF 25% in diabetic 
patients shows that the ‘P’ value is <0.0001 which is significant.  
 The comparison of preoperative and postoperative FEF 25% in non 
diabetic patients shows that the ‘P’ value is 0.0584 which is not significant. 
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Table D5 :Preoperative and Postoperative PEFR 
PEFR Value 
Diabetic Patients Non Diabetic Patients 
Mean SD Mean SD 
Pre operative 74.4 4.4 77.1 6.8 
Post Operative 59.1 3.4 76.3 5.6 
‘p’ <0.0001 Significant 0.5205 Not significant 
 
The comparison of preoperative and postoperative PEFR in diabetic 
patients shows that the ‘P’ value is <0.0001 which is significant.  
 The comparison of preoperative and postoperative PEFR in non diabetic 
patients shows that the ‘P’ value is 0.5205 which is not significant. 
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DISCUSSION 
The result of this study shows that the pulmonary function test parameters 
such as FEV1, FVC, FEF25%, PEFR are significantly reduced except 
FEV1/FVC in type 2 diabetic patients undergoing elective major abdominal 
surgeries under general anesthesia when compared to the non diabetic patients.  
This significant difference occurs both preoperatively and postoperatively but 
the postoperative difference is highly significant clinically.  
           A similar study conducted by shah, et al. Showed that the pulmonary 
function tests were significantly decreased in diabetic patients when compared 
to the non  diabetic healthy control subjects except FEV1/FVC causing a 
restrictive pattern  of ventilator change. They also found out that there is no 
significant correlation between FVC and FEV1 with the duration of diabetes 
and glycosylated haemoglobin.  
          A study conducted by Van den Borst, et al. found out that the diabetes 
mellitus is associated with a statistically significant restrictive pattern of   
reduced lung function which is irrespective of body mass index, duration of 
diabetes and glycosylated haemoglobin. 
           The pathophysiology behind this is that reduced lung function in diabetic 
patients is the alteration in the alveolar-capillary network in the lungs producing 
microangiopathic changes. The alteration in the surfactant action of the alveoli, 
accelerated ageing process in the connective tissue cross links and the presence 
of non enzymatic glycosylation results in reduced lung functions. The non 
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enzymatic glycosylation leads to stiffening of lung parenchyma which results in 
restrictive pattern of lung disease.  The increase in thickness of epithelium of 
alveoli, thickness of the capillary endothelium and basal laminae thickening are 
seen in the lungs of diabetic patients on electron microscopy. 
         The limitation of this study is that the correlation between pulmonary 
function tests with the duration of diabetes and glycosylated haemoglobin 
(HbA1c) could not be made out in this study. Another limitation is that whether 
the supplementation of epidural analgesia can provide improvement the 
pulmonary functions postoperatively could not be made out in this study. 
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SUMMARY 
 
In this study, we evaluate the pulmonary function tests in type 2 diabetic 
patients.100 ASA 1 and ASA 2 patients of either sex were divided into two 
groups, 50 patients in each group. 
 
• Group 1 includes type 2 diabetic patients who were undergoing elective 
major abdominal surgeries under general anesthesia.  
 
• Group 2 includes non diabetic patients who were undergoing elective major 
abdominal surgeries under general anesthesia. 
 
The study was done at Govt. Rajaji hospital and Madurai Medical College, 
Madurai between the period of  2012- 2014.   
 
In our study the age of the patients, sex distribution , height, weight, BMI, 
duration of surgery were not statistically significant between the study group 
and control group. 
 
Preoperative comparison of pulmonary function tests in diabetic and non 
diabetic patients shows a statistically significant decrease in FEV1, FVC, FEF 
25%, PEFR except FEV1/FVC.  
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Postoperative comparison of pulmonary function tests in diabetic and non 
diabetic patients shows a statistically significant decrease in FEV1, FVC, 
FEF25%, PEFR except FEV1/FVC. 
Preoperative and postoperative comparison of pulmonary function tests in 
non diabetic patients shows decrease in FEV1, FVC, FEF25%, PEFR  but this is 
not statistically significant. 
Preoperative and postoperative comparison of pulmonary function tests in 
diabetic patients shows a statistically significant decrease in FEV1, FVC, 
FEF25%, PEFR except FEV1/FVC. 
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CONCLUSION 
 
                From this study, it is concluded that pulmonary function tests are 
impaired in diabetic patients both preoperatively and postoperatively when 
compared to the non diabetic patients and is statistically significant.  
              The impairment of pulmonary function tests in diabetic patients 
postoperatively shows that this impairment is also significant clinically.  
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                                                  PROFORMA 
 
Name                :                   IP. NO: 
Age & sex            :                                       ASA: 
Height                  : 
Weight                 : 
BMI                     : 
Date of admission :     Date of Discharge: 
 
Diagnosis              : 
 
History                   : Smoking, duration of diabetes, cardiovascular or  
                                  respiratory symptoms. 
 
Clinical examination:   
PR, BP, SPO2, CVS, RS. 
 
Investigations      :  
FBS, PPBS, blood urea, serum creatinine,Urine sugar, ECG. 
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PREOPERATIVE PFT  
(60 MINUTES BEFORE SURGERY) 
PARAMETERS 
% PREDICTED 
VALUES 
DIADETIC PATIENTS 
NON DIABETIC 
PATIENTS 
         FEV1   
         FVC   
        FEV1/FVC   
       FEF 25%   
        PEFR   
  
POSTOPERATIVE PFT  
(60 MINUTES AFTER THE END OF SURGERY) 
PARAMETERS 
% PREDICTED 
VALUES 
DIABETIC PATIENTS 
NON DIABETIC 
PATIENTS 
         FEV1   
         FVC   
         FEV1/FVC   
         FEF 25%   
          PEFR   
 
Sl.
No. NAME AGE SEX IP. NO GROUP
HEIGHT
(CM)
WEIGHT
(KG) BMI
DURATION 
OF 
SURGERY
(MINS)
PRE
FEV1
PRE 
FVC
PRE 
FEV1/
FVC
PRE 
FEF
25%
PRE 
PEFR
POST
FEV1
POST 
FVC
POST 
FEV1/
FVC
POST
FEF
25%
POST
 PEFR
1 GANESAN 55 M 35834 ND 162 68 25.95 90 90 80 113 77 78 87 78 112 75 70
2 MARIMUTHU 58 M 38257 ND 158 62 24.89 175 88 84 105 86 75 88 80 110 78 76
3 RAJA 56 M 31062 ND 168 58 20.56 150 92 89 103 88 66 87 82 106 80 75
4 KUPPAMMAL 42 F 38587 ND 156 52 21.39 140 89 88 101 78 67 86 80 108 79 72
5 SHANMUGAM 54 M 37865 ND 167 59 21.22 120 87 82 106 87 88 88 82 107 85 80
6 SUGUBAR NISHA 56 F 31299 ND 157 65 26.42 145 85 80 106 78 87 82 77 106 75 70
7 THANGAM 45 F 23647 ND 154 57 24.05 130 89 80 111 79 69 85 84 101 78 67
8 SEKAR 52 M 35927 ND 169 69 24.21 125 85 82 104 87 89 84 79 106 86 75
9 KARTHIK 48 M 38918 ND 169 85 29.82 130 89 83 107 78 68 83 80 104 85 65
MASTER CHART 
 PULMONARY FUNCTION TESTS IN NON DIABETIC PATIENTS 
10 VASANTHI 52 F 40651 ND 160 57 22.26 145 90 86 105 83 71 88 82 107 80 65
11 KANDASAMY 46 M 41538 ND 167 59 21.22 130 94 85 111 86 82 92 87 106 82 84
12 PANDEESWARI 49 F 42059 ND 163 53 20 145 85 81 105 84 80 90 82 110 80 78
13 AMSAVALLI 52 F 41507 ND 158 54 21.68 135 82 82 100 84 67 88 83 106 79 80
14 RAVI 54 M 36130 ND 167 89 32.1 160 87 86 101 88 73 88 78 113 85 79
15 VELSAMY 57 M 54321 ND 167 89 32.01 180 92 88 105 89 72 92 82 112 87 73
16 KALIAMMAL 53 F 53472 ND 158 58 23.29 125 93 81 115 87 70 85 78 109 83 68
17 RAJATHI 45 F 50348 ND 159 58 23.01 110 83 83 100 87 68 91 85 107 86 65
18 AMBIGA 48 F 52360 ND 157 62 25.2 100 90 81 111 85 75 85 76 112 84 73
19 SHIVA 45 M 53683 ND 169 64 22.45 95 93 82 113 80 78 90 82 110 85 74
20 GOMATHY 53 F 53938 ND 158 65 26.1 115 92 84 110 79 83 83 84 99 76 79
21 LOORTHUMARY 57 F 55502 ND 157 62 25.2 130 85 80 106 78 82 91 83 110 84 76
22 RAGUNATHAN 52 M 54791 ND 168 68 24.11 90 84 80 105 89 76 80 75 107 88 73
23 SATHYANATHAN 46 M 54613 ND 170 78 26.98 140 89 81 110 86 67 84 78 108 84 76
24 ANNADURAI 48 M 57149 ND 169 72 25.26 150 87 83 105 83 68 80 76 105 80 77
25 RAMASAMY 46 M 56450 ND 172 82 27.79 130 88 82 107 85 89 81 79 103 81 76
Sl.No. NAME AGE SEX IP. NO GROUP HEIGHT(CM)
WEIGHT
(KG) BMI
DURATION 
OF 
SURGERY
(MINS)
PRE
FEV1
PRE 
FVC
PRE 
FEV1/
FVC
PRE 
FEF
25%
PRE 
PEFR
POST
FEV1
POST 
FVC
POST 
FEV1/
FVC
POST
FEF
25%
POST
 PEFR
26 PANDI 46 M 56251 ND 169 57 20 115 86 81 106 81 78 88 80 110 86 82
27 KAVITHA 47 F 58311 ND 152 53 22.94 100 84 81 104 75 75 80 74 108 82 81
28 ILAYARAJA 56 M 59800 ND 166 61 22.18 115 80 80 100 72 77 84 78 108 82 84
29 DHANALAKSHMI 54 F 56438 ND 158 53 21.28 125 85 81 105 86 73 85 77 110 80 83
30 BANUPRIYA 52 F 56255 ND 156 66 27.16 135 87 82 106 84 79 80 73 110 78 85
31 VALAYUTHAM 48 M 17422 ND 167 57 20.5 170 83 83 100 89 84 90 82 110 88 80
32 KARUPPIAH 51 M 18365 ND 169 59 20.7 155 91 80 114 82 83 93 89 104 80 86
33 ESWARAN 50 M 13366 ND 168 63 22.34 160 94 89 106 85 87 85 82 104 81 80
34 IRULAMMAL 56 F 18261 ND 160 53 20.7 120 89 85 105 80 76 88 83 106 78 84
MASTER CHART
PULMONARY FUNCTION TESTS IN NON DIABETIC PATIENTS 
35 SARASWATHI 54 F 18891 ND 163 56 21.13 140 91 81 112 83 72 86 80 108 80 78
36 MARIAPPAN 58 M 89555 ND 168 64 22.69 130 94 82 115 89 89 89 82 109 87 85
37 VENKATESH 45 M 18475 ND 170 65 22.49 135 83 80 104 78 68 82 74 111 80 81
38 ANGUSAMY 46 M 97717 ND 168 68 24.11 120 84 82 102 86 86 91 85 107 85 78
39 PANDEESWARI 56 F 90998 ND 158 58 23.29 145 89 80 111 81 74 86 78 110 78 83
40 NEELAVATHI 53 F 97793 ND 162 55 20.99 150 85 78 109 83 70 84 78 108 80 76
41 SRINIVASAN 55 M 34201 ND 169 64 22.45 135 87 80 109 85 75 82 77 106 80 72
42 VISHNU 43 M 4067 ND 171 68 23.28 90 82 83 99 87 79 88 79 111 88 70
43 MUNIASAMY 42 M 5138 ND 169 60 21.05 145 91 81 112 88 80 87 83 105 83 77
44 SATHYA 57 F 4517 ND 159 59 23.41 125 89 80 111 82 75 88 82 107 80 70
45 PREMA 60 F 6202 ND 160 48 18.75 150 94 84 112 87 76 90 84 107 83 74
46 GOPAL 49 M 98055 ND 168 57 20.21 130 92 82 112 85 85 87 79 110 81 82
47 POTHUM PONNU 54 F 3421 ND 159 46 18.25 140 91 81 112 84 83 92 82 112 80 78
48 MURUGESWARI 58 F 7592 ND 157 51 20.73 145 89 81 110 79 80 86 76 113 85 72
49 JOSEPH 49 M 2439 ND 169 63 22.1 150 90 84 107 81 78 93 86 108 86 73
50 KUMARAN 56 M 9294 ND 168 58 20.56 120 95 86 110 85 84 90 84 107 80 74
Sl.
No. NAME AGE SEX IP. NO GROUP
HEIGHT
(CM)
WEIGHT
(KG) BMI
DURATION 
OF 
SURGERY
(MINS)
PRE
FEV1
PRE 
FVC
PRE 
FEV1/
FVC
PRE 
FEF
25%
PRE 
PEFR
POST
FEV1
POST 
FVC
POST 
FEV1/
FVC
POST
FEF
25%
POST
 PEFR
1 THIRUMALAI 54 M 5843 D 168 78 27.65 150 78 82 95 85 70 68 61 111 59 63
2 SARAVANAN 53 M 10255 D 166 72 26.18 170 85 77 110 83 77 72 70 103 66 61
3 SRIDEVI 45 F 94465 D 158 52 20.88 185 84 79 106 82 74 70 64 109 63 64
4 HEMA 47 F 2836 D 160 56 21.87 165 89 86 103 78 67 78 73 107 56 57
5 THENNARASU 45 M 6849 D 167 68 24.46 190 91 82 111 85 66 77 68 113 60 55
6 RAJENDRAN 49 M 12473 D 166 62 22.54 140 87 82 106 83 81 63 57 111 58 54
7 PANDI 57 M 3408 D 170 74 25.6 130 84 80 105 72 70 64 59 108 60 57
8 MEENA 56 F 6691 D 160 52 20.31 110 85 82 104 74 77 70 65 108 55 61
9 ANANDAVALLI 60 F 9012 D 158 54 21.68 145 86 80 108 73 79 73 63 116 58 65
10 RAJESWARI 55 F 11128 D 159 56 22.22 160 83 85 98 68 74 81 69 117 56 58
MASTER CHART
PULMONARY FUNCTION TESTS IN DIABETIC PATIENTS 
11 KASTHURI 59 F 13461 D 158 56 22.48 135 90 84 107 76 78 76 76 100 60 64
12 MURALI 53 M 13074 D 166 62 22.54 160 79 73 108 79 79 67 63 106 62 62
13 MANI 54 M 14355 D 168 56 19.85 140 87 82 106 75 81 66 59 112 58 67
14 MAHALINGAM 58 M 15301 D 167 70 25.17 125 82 84 98 76 75 64 57 112 59 56
15 LAKSHMI 44 F 13892 D 152 50 21.64 110 88 84 105 73 72 75 66 114 58 57
16 RAJAMMAL 42 F 1790 D 162 56 21.37 100 90 83 108 87 73 77 73 105 65 58
17 BALAMURUGAN 48 M 13241 D 166 66 24 140 84 81 104 90 78 68 62 110 67 55
18 GANAPATHY 56 M 18325 D 168 67 23.75 125 80 80 100 82 75 69 66 105 59 64
19 MUTHU 52 M 36297 D 170 59 20.41 160 82 78 105 84 76 66 60 110 69 58
20 KRISHNAVENI 55 F 10231 D 158 55 22.08 125 84 80 105 89 68 71 67 106 70 60
21 AMSALAKSHMI 58 F 19106 D 162 57 21.75 115 83 79 105 87 71 73 68 107 61 57
22 SARAVANAN 49 M 16530 D 170 67 23.18 90 82 77 106 81 65 67 64 105 55 56
23 ALAGU 45 F 26252 D 159 62 24.6 110 83 78 106 83 69 69 62 111 60 63
24 KALIDEVI 56 F 29631 D 163 65 24.52 150 84 80 105 83 69 66 61 108 59 60
25 KOTTASAMY 55 M 28909 D 167 69 24.82 145 84 80 105 84 74 69 63 110 60 55
Sl.
No. NAME AGE SEX IP. NO GROUP
HEIGHT
(CM)
WEIGHT
(KG) BMI
DURATION 
OF 
SURGERY
(MINS)
PRE
FEV1
PRE 
FVC
PRE 
FEV1/
FVC
PRE 
FEF
25%
PRE 
PEFR
POST
FEV1
POST 
FVC
POST 
FEV1/
FVC
POST
FEF
25%
POST
 PEFR
26 RAJA 58 M 29413 D 168 67 23.75 160 84 80 105 79 78 71 64 111 62 56
27 SAROJA 53 F 30360 D 159 56 22.22 130 83 79 105 78 76 64 57 112 58 55
28 MALAR 59 F 27241 D 157 53 21.54 120 81 78 104 80 74 72 64 113 54 59
29 HARIHARAN 52 M 30099 D 169 63 22.1 110 86 84 102 83 74 69 59 117 69 58
30 VALARMATHI 50 F 23980 D 162 54 20.61 115 85 81 105 81 73 70 65 108 68 58
31 SELVAM 49 M 29894 D 170 65 22.49 120 81 79 103 80 83 71 67 106 63 62
32 THAMARAI 44 F 29864 D 160 52 20.31 150 92 86 107 78 75 64 58 110 65 60
33 ANBURAJ 58 M 34397 D 171 68 23.28 145 94 88 107 85 71 69 57 121 66 63
34 CHITRA 51 F 32598 D 159 56 22.22 150 80 77 104 79 68 70 61 115 65 58
PULMONARY FUNCTION TESTS IN DIABETIC PATIENTS 
MASTER CHART
35 BASKARAN 48 M 37597 D 166 66 24 110 87 83 105 78 69 64 58 110 58 58
36 PANDIAN 56 M 37829 D 168 69 24.46 100 80 78 103 85 75 67 62 108 67 62
37 NAGARAJ 47 M 39713 D 168 72 25.53 115 82 83 99 87 78 72 70 103 68 58
38 MARIAMMAL 58 F 40668 D 158 55 22.08 140 80 76 105 82 87 63 60 105 63 64
39 RAMANATHAN 54 M 42500 D 167 59 21.22 95 82 78 105 87 72 64 59 108 65 58
40 MALLIKA 57 F 20354 D 160 57 22.26 110 82 78 105 84 74 70 61 115 66 59
41 CHANDRAN 46 M 51635 D 168 64 22.69 120 87 81 107 81 73 68 62 110 65 67
42 KALIAPPAN 57 M 55584 D 169 68 23.85 90 89 83 107 82 75 71 64 111 68 55
43 SHANTHI 55 F 53413 D 163 56 21.13 105 84 80 105 79 76 68 58 117 65 54
44 DEVADOSS 52 M 62395 D 166 69 25.09 110 82 78 105 76 79 64 57 112 67 57
45 NANDHINI 57 F 57894 D 159 52 20.63 105 88 84 105 79 75 69 61 113 63 58
46 VELU 53 M 52051 D 169 61 21.4 130 83 79 105 85 76 68 62 110 68 56
47 ELAVARASAN 57 M 63386 D 168 62 21.98 125 84 78 108 77 74 67 59 114 64 63
48 LAKSHMI 53 F 69878 D 160 54 21.09 115 85 79 108 83 73 65 60 108 65 56
49 VALLI 55 F 73479 D 162 55 20.99 105 88 85 104 80 77 71 70 101 68 58
50 MUNIYAMMAL 59 F 84976 D 158 57 22.89 100 82 77 106 84 76 67 63 106 66 57
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